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Introduction, aims and outline

9INTRODUCTION
DISEASE PRESENTATION AND EPIDEMIOLOGY
Autoimmune pancreatitis (AIP) is the pancreatic manifestation of a 
systemic fibro- inflammatory disease, characterized by infiltration with 
lymphoplasmacytic cells and extensive fibrosis, which leads to morphological 
changes (swelling, mass forming) and organ dysfunction.1 Often, but not 
always, the disease is characterized by elevated levels of serum IgG4 and 
IgG4 positive plasma cells in the affected tissues.2-3 The disease was initially 
described by Sarles in 1961.4 A major breakthrough was the identification in 
2001 of serum IgG4 levels as biomarker.2 IgG4 levels are elevated in 68 - 95% 
of patients with AIP.2, 5-9 The concept of IgG4-related systemic disease was 
adopted in 2003.10 Currently two types of AIP are recognized: type 1 which 
is associated with IgG4-related disease, and type 2, which has substantial 
clinical overlap but distinctive pathological features.11 There are little data 
on global incidence and prevalence of AIP. Virtually all data regarding 
epidemiology comes from Japan. Based on these data, the estimated prevalence 
is 2.2/100.000, with an annual incidence rate of 0.9/100.000.12 It is believed 
that AIP accounts for 5 - 6% of all patients with chronic pancreatitis. In patients 
who underwent resection for presumed malignancy, AIP is found in 2.5%.13 The 
male to female ratio is 3.7 and the mean age is 63 years.12 The typical clinical 
presentation is that of an older man with jaundice, diffuse or focal pancreatic 
enlargement or mass, substantial weightloss and recent onset diabetes. 
Other organ involvement is common in the course of AIP. Usually it coincides 
with or follows the pancreatic manifestation, but sometimes it may herald AIP. 
The biliary tree, salivary glands, retroperitoneum, kidneys and lymph nodes 
are involved most frequently, which may lead to sclerosing cholangitis, Sjögren 
like syndrome, retroperitoneal fibrosis, interstitial nephritis, pseudotumors 
in lungs or liver and generalized or localized lymphadenopathy.1, 14 
Spontaneous remissions and relapses are common. The disease is highly 
responsive to steroids15-16 and this can be used as a diagnostic tool.17
DIAGNOSIS
Because of its clinical resemblance with other pancreatobiliary diseases, 
including malignancy, diagnosis is often troublesome (Figure 1 - 3). Correct 
diagnosis at an early stage is crucial to prevent both unnecessary and 
potentially harmful surgery in AIP patients, as well as steroid trials with 
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Figure 1 CT scan. 
This patient was primarily diagnosed with cholangiocarcinoma with liver metastases. 
Two years later, a diagnosis of AIP with sclerosing cholangitis was made. The liver lesions 
proved to be cysts, diffuse pancreatic swelling with hypodense rim was already present 
initially, but not recognized.
A B
Figure 2 ERCP of same patient as Figure 1.
A. Two stenoses of hepatocholedochal duct, a biliary stent was placed.
B. Response to steroid therapy
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subsequent delay of effective treatment in cancer patients.18 Therefore 
exclusion of malignancy is the first step in the diagnostic process. To confirm 
a diagnosis of AIP, histology is considered the gold standard.19 In resection 
specimens diagnosis can be made relatively easy, but is represents failure 
of timely diagnosis. Cytology is important to exclude malignancy, but lacks 
sufficient diagnostic performance to establish the diagnosis of AIP.20 Fine 
needle biopsy is promising in expert hands21-22 but is not routinely available 
in everyday gastroenterology practice. There is no single diagnostic test to 
diagnose AIP, but diagnosis can be confirmed by the use of diagnostic criteria, 
combining radiological (diffuse or focal enlargement, occasionally with 
rim enhancement, diffuse or segmental narrowing of the pancreatic duct), 
histological (lymphoplasmacytic sclerosing pancreatitis and IgG4 staining in 
type 1, granulocyitic epithelial lesions in type 2), serological (IgG4, IgG and 
the presence of autoantibodies like rheumatoid factor or antinuclear antibody) 
and other criteria such as other organ involvement and response to steroid 
therapy (Table 1). Numerous sets of diagnostic criteria have been proposed. 
The Asian criteria23 and HISORt criteria19 are used most frequently. In the Asian 
criteria, radiology is crucial, in particular diagnostic pancreatography. HISORt 
criteria enable diagnosis through different approaches: IgG4, steroid trial or 
histology. Recently the extensive International Consensus Diagnostic Criteria 
of AIP have been accepted and published.24 For use in clinical practice, these 
Figure 3 Nodular pulmonary lesion in the right upper lobe, suspicious of malignant 
tumor. Histology showed fibrosis and IgG4 positive cells.
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systems harbor their own pros and cons. The Asian criteria are easy and 
straightforward to use but a pancreatogram is always required. This contrasts 
with common European and American gastroenterology practice in which in 
case of suspected pancreatic cancer, early surgery is preferred over endoscopic 
retrograde cholangio-pancreatography (ERCP) / biliary drainage.25 Moreover, 
to avoid post-ERCP pancreatitis, gastroenterologists usually do not attempt to 
deliberately cannulate and fill the pancreatic duct.26 A non-invasive modality 
such as magnetic resonance cholangio-pancreatography (MRCP) is still inferior 
to ERCP in detecting the subtle ductal changes in AIP.27 HISORt criteria are 
somewhat more complicated but quite elegant, enabling a diagnosis of AIP 
from different angles. The ICDC are very elaborate. They encompass all kind of 
difficult diagnostic situations which might improve sensitivity, but consequently 
complicate its application. This renders ICDC unsuitable for use in routine daily 
practice.
PATHOGENESIS
The pathogenesis of AIP remains to be elucidated. The current understanding 
is that in genetically susceptible persons,28-29 an autoimmune reaction 
(Th1 mediated) or infectious agent (through molecular mimicry or innate 
immunity) triggers a Th2 mediated (allergic) immune response which 
leads to excessive or inappropriate B cell activation.30-33 It is not known 
whether IgG4, classically known as an anti-inflammatory immunoglobulin,34 
is pathogenic or an epiphenomenon. Although numerous general and 
Table 1 Diagnostic criteria for autoimmune pancreatitis
Radiology Diffuse or focal enlarged pancreas with hypodense rim
Diffuse or focal narrowing of pancreatic duct
Rarely pancreatic calcifications or cysts
Serology Elevated IgG or IgG4 (> 2x ULN), presence of autoantibodies (ANA, RF)
Other organ 
involvement
Sclerosing cholangitis, parotid/lacrimal gland enlargement, 
retroperitoneal fibrosis, interstitial nephritis, mediastinal or 
generalized lymphadenopathy, inflammatory tumors lungs and liver, 
inflammatory bowel disease
Response to therapy prednisone 0.5 mg/kg/d, during 2 weeks
Histology Type 1: lymphoplasmacytic infiltration with fibrosis or
IgG4 positive plasmacells (> 10 /hpf)
Type 2: idiopathic duct centric pancreatitis or granulocyte epithelial 
lesion
Simplified summary of Asian and HISORt criteria.19,23 Abbreviations ULN = upper limit of 
normal, hpf = high power field.
13
pancreas-specific auto antigens have been proposed as initial trigger,35 
sufficient evidence is lacking. In 2009 Helicobacter pylori was launched 
as causal agent,36 but results have not been confirmed yet.
TREATMENT AND PROGNOSIS
The treatment of AIP consists of three modalities: immunosuppression, 
supportive therapy and surgery. Although surgery is considered synonymous 
with failure of the diagnostic process, it is still inevitable in a substantial 
number of patients, mainly because malignancy could not be ruled out 
properly. In high volume centers, mortality is less than 5%37 and is still 
decreasing.38-39 Relapse is less common after surgery than after steroid therapy 
(20% versus 25 - 60%).40-41 Supportive therapy includes biliary decompression 
by endoscopic stent placement (which also provides important diagnostic 
information), suppletion of pancreatic enzymes in case of exocrine insufficiency 
and treatment of diabetes. Steroid therapy is the corner stone in AIP treatment 
and is highly effective. Response rates are excellent (98%),42 but relapses are 
common. Recommended induction doses are 30 to 40mg/day during 4 weeks, 
comparable with schemes used in other autoimmune diseases. Since AIP 
is highly responsive to steroids, the need of such high induction dose is 
debatable. We noticed excellent responses in several patients with low dose 
prednisone (10 to 20 mg), but this finding was neither confirmed in literature 
nor commonplace. After the initial phase, the dose can be tapered gradually 
(usually 5mg/week) and stopped after 3 months (recommended in the USA). 
In a nationwide study in Japan, long-term (2 - 3 years) maintenance therapy 
was recommended with low dose (2.5 to 10mg/day). The relapse rate with 
maintenance treatment was 23%, which was significantly lower than in patients 
who stopped (34%, p=0.048).42 Despite the excellent initial response rates, 
relapse is common, especially in patients with proximal biliary involvement.40-41 
Persistently high values of IgG4 are not predictive of relapse.41 In case of 
relapse, another course of steroids is equally effective.42 Step up therapy with 
immunomodulators like azathioprine, 6-mercaptopurine or mycophenolate 
mofetil can be used.43 Although the steroid-sparing concept is attractive and 
has been proven effective in other autoimmune disease, its efficacy in AIP has 
not been demonstrated conclusively. Recently selective B-cell depletion therapy 
by rituximab, a monoclonal antibody directed against the CD20 antigen on 
B-cells, was shown to be effective in steroid-refractory or relapsing disease.43
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In most patients the long-term prognosis is excellent. A small subset of patients 
will be diagnosed in the chronic phase, with chronic pancreatitis (with or 
without exocrine insufficiency), or less common with pseudocyst formation, 
pancreatic duct stones or vascular complications like splenic vein thrombosis. 
Sequels of extrapancreatic manifestations like liver fibrosis / cirrhosis and 
chronic renal failure may cause substantial morbidity and mortality. AIP may be 
a risk factor of pancreatobiliary cancer, but the exact risk and its subsequent 
implications for long term follow-up and surveillance are unknown.44
AIMS
We aimed to characterize a group of 114 AIP patients and explore the 
performance of the three major diagnostic criteria systems in this group. 
Second we aimed to determine the extent and cause of misdiagnosis in 
patients that underwent resection for presumed malignancy of the pancreatic 
head. Furthermore we examined the serological profile, including serum 
total IgE and tumor marker Ca 19 - 9 in AIP and other pancreatobiliary 
disorders with a dual purpose: explore their value in differential diagnosis 
with malignancy and gain insight into pathogenesis. Finally we aimed to 
compare the efficacy of low dose versus high dose steroid induction therapy.
OUTLINE
In Chapter 2 a multicenter national cohort of 114 AIP patients is characterized. 
In this retrospective study the performance of the three major diagnostic 
criteria systems of AIP is investigated. Ultimately, recommendations are made 
which system should preferably be used in specific situations. In Chapter 3 we 
retrospectively analyze all pancreatoduodenectomies performed for presumed 
malignancy of the pancreatic head in the Erasmus University Medical Center, 
in a 9 year period. The number and type of benign diseases are established 
including the prevalence of AIP. The preoperative work up is evaluated and 
recommendations are made how to prevent unnecessary surgery.
The tumor marker Ca 19 - 9 is often elevated in pancreatic and biliary 
carcinoma. Marked elevation (> 300 kU/L) is generally considered highly specific 
for malignancy.45 In AIP however, very high levels are sometimes observed and 
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may prompt clinicians to embark on surgery. In search of an optimal cut-off 
level of Ca 19 - 9 to differentiate between AIP and pancreatic cancer, we study 
the Ca 19 - 9 levels in AIP and other benign and malignant pancreatobiliary 
diseases in Chapter 4. Moreover, IgG4 and Ca 19 - 9 levels are combined to 
improve diagnostic performance.
We are in need of new, preferably serological tests with sufficient sensitivity 
and specificity. Evidence shows that both autoimmune and allergic mechanisms 
are important in the inflammatory cascade observed in AIP. Most studies on 
serological markers focus on autoimmunity. This is also reflected in the fact 
that the presence of auto-antibodies is incorporated in several diagnostic 
criteria systems of AIP. In search of the triggering antigen, numerous general 
and pancreas-specific antigens are proposed. In general the results of these 
studies on auto-antibodies lack validation and reproducibility. Compared to 
the numerous studies on autoimmunity, the role of allergic mechanisms has 
been underexposed. In chapter 5 a pilot study describes the relation between 
serum total IgE and IgG4 in AIP, atopic allergy and pancreatic carcinoma. 
Furthermore the potential value of serum total IgE in the differentiation between 
AIP and pancreatic carcinoma is studied. In Chapter 6 an extensive serological 
profile, including several auto-antibodies, is determined in AIP and various 
pancreatobiliary diseases. The diagnostic performance of each test is assessed 
to differentiate between AIP and malignancy. Ultimately a logistic regression 
analysis is performed to detect combinations of tests that reliably predict AIP.
Chapter 7 focuses on steroid treatment in AIP. Guided by treatment regimens of 
other gastrointestinal autoimmune diseases like inflammatory bowel disease, 
current guidelines recommend high doses of steroid induction therapy. Steroids, 
especially high dose, are notorious because of side-effects like triggering or 
worsening of pre-existing diabetes mellitus, osteoporosis and psychological 
disturbances. These side effects are particularly inconvenient in the older 
diabetic AIP patient. AIP is responsive to steroids to such an extent that the 
rationale of high dose should be questioned. Chapter 7 shows the results of a 
retrospective study comparing the efficacy of low and high dose corticosteroid 
induction therapy.
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ABSTRACT
Objective Several diagnostic scoring systems for autoimmune pancreatitis 
have been proposed including the Asian, HISORt and International Consensus 
Diagnostic Criteria. Few studies have compared the diagnostic performance 
of these scoring systems. We aimed to explore the diagnostic performance of 
these criteria in a group of patients diagnosed with AIP between May 1992 and 
August 2011. 
Methods Scoring systems were applied retrospectively using data obtained in 
the initial evaluation period, before pancreatic resection was performed. 
Results 114 cases with AIP were included. 82% met the diagnostic criteria 
for AIP according to either the Asian, HISORt or ICDC criteria. Only 33% 
met the Asian criteria, probably mainly related to a low rate of diagnostic 
pancreatography. In 18% all scoring systems failed to confirm the diagnosis, 
even though these patients were considered to have a firm diagnosis of AIP. 
Conclusions In this cohort of mainly type 1 AIP patients, the three major 
diagnostic scoring systems for AIP proved to be complementary rather than 
overlapping. Our data indicate that one-fifth of patients suffer from AIP 
while they do not meet any of these scoring systems. The Asian, HISORt and 
International Consensus Diagnostic Criteria should be considered as useful 
clinical tools but not as gold standard for the diagnosis.
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INTRODUCTION
Autoimmune pancreatitis (AIP) represents the pancreatic manifestation of 
IgG4-related sclerosing disease that may affect not only the pancreas but 
also other organs including the extrapancreatic biliary tract, salivary glands, 
retroperitoneal tissues, and kidneys.1 Since AIP often presents in men in their 6th 
or 7th decade, with jaundice, weight loss and a pancreatic mass, the differential 
diagnosis is focused mainly on malignancy. Recently, the Honolulu consensus 
meeting agreed on the presence of two distinct histological and clinical types 
of AIP: lymphoplasmacytic sclerosing pancreatitis (LPSP) / type 1 and idiopathic 
duct-centric pancreatitis (IDCP) / type 2.2-4 Whereas type 1 represents the 
classical phenotype as described above, type 2 patients present younger (4th 
decade), without male preponderance. Abdominal pain and acute pancreatitis 
are observed more often. IgG4 elevation is rarely observed. Inflammatory bowel 
disease is often associated, other organ manifestations are rare. Response to 
steroids is good, with less recurrence (40 - 50% in type 1, 0 - 25% in type 2).1, 3-6 
The histological hallmark of type 2 is destruction of ductal epithelium by GELs 
(granulocyte epithelial lesions). Fibrosis is less common and IgG4 positive 
cells are scant or absent. Since there is no serological marker and other organ 
involvement (OOI) is uncommon, the autoimmune nature of AIP type 2 is a 
matter of debate.2
There is no single diagnostic test to diagnose AIP, but diagnosis can be 
confirmed using diagnostic scores combining radiological (diffuse or focal 
enlargement, occasionally with rim enhancement, diffuse or segmental 
narrowing of the main pancreatic duct), histological (LPSP and IgG4 staining 
in type 1 AIP, GELs in type 2 AIP), serological (IgG4, IgG and the presence 
of autoantibodies) and other criteria such as involvement of other organs 
(sclerosing cholangitis, interstitial nephritis, retroperitoneal fibrosis or 
Sjögren-like syndrome) and response to steroid therapy.7-9 The Asian criteria 
(2008)8 and HISORt criteria (acronym for Histology, Imaging, Serology, Other 
organ involvement and Response to therapy), Mayo Clinic, 2006,7 revised in 
200910) are used most frequently. The Asian criteria are relatively easy to apply 
but require diagnostic pancreatography. Diagnosis is made in combination 
with either serology, histology or response to therapy. The HISORt criteria, 
categorizing patients in three groups, enable diagnosis solely based on 
histology, which gives special significance to pancreatic core biopsy (group 
A). Other ways to make diagnosis are: radiology in combination with IgG4 
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positivity or other -histologically proven - OOI (group B), and unexplained 
pancreatic disease, IgG4 positivity and response to therapy (group C). In group 
B and C, IgG4 positivity is mandatory. Recently, the International Consensus 
Diagnostic Criteria (ICDC) were developed, based on aforementioned systems in 
combination with proposed Italian6 and German criteria.11
For use in daily clinical practice, these systems harbor their own pros and cons. 
The Asian criteria are easy and straightforward to use but a pancreatogram 
is always required. This contrasts with common European and American 
gastroenterology practice in which in case of suspected pancreatic cancer, early 
surgery is preferred over endoscopic retrograde cholangio-pancreatography 
(ERCP) / biliary drainage.12 Moreover, to avoid post-ERCP pancreatitis, 
gastroenterologists usually do not attempt to deliberately cannulate and fill 
the pancreatic duct.13 A non-invasive modality such as magnetic resonance 
cholangio-pancreatography (MRCP) is still inferior to ERCP in detecting the 
subtle ductal changes in AIP.14 HISORt criteria are somewhat more complicated 
but quite elegant, enabling a diagnosis of AIP from different angles. The ICDC 
are very elaborate. They encompass all kind of difficult diagnostic situations 
which might improve sensitivity, but consequently complicate its application. 
This renders ICDC unsuitable for use in routine daily practice. The use of 
histology based criteria, part of all systems, poses some limitations and 
challenges. Histology obtained with resection is considered gold standard, 
but actually represents failure of the system to timely diagnose AIP, that 
is before resection. Histology obtained with endoscopic ultrasonography 
(EUS) core biopsy, although very attractive in expert hands,15-16 is limited by 
sampling error, is not routinely available in daily gastroenterology practice 
and requires a pathologist familiar with the diagnosis and IgG4 staining.
For these reasons we aimed to investigate the diagnostic performance of all 
three scoring systems, using the data on initial clinical presentation, with 
emphasis on preoperative data.
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MATERIALS AND METHODS
Patients diagnosed with AIP between May 1992 to August 2011 were enrolled 
in this multicentre retrospective study. They were included if the ICDC, Asian 
or HISORt criteria were fulfilled. In addition, patients were eligible when 
post-surgery pancreatic histology allowed an unequivocal diagnosis of AIP 
or when otherwise unexplained pancreato-biliary disease or extrapancreatic 
manifestations were diagnosed in combination with either response to 
steroids or IgG4-positive serology. Clinical data, laboratory and imaging 
findings, histology, response to treatment, and recurrence were studied to 
characterize the patient population. The radiological data were reviewed by a 
radiologist, expert pancreatologist and research fellow independently. In case of 
disagreement, cases were reviewed by the entire panel. Histological evaluation 
was performed by two expert pathologists familiar with IgG4 staining and 
specialized in hepatic, pancreatic and biliary pathology. If not performed 
already, immunostaining was performed using a monoclonal mouse anti-human 
IgG4 (Zymed Laboratories, San Francisco, USA), with a working dilution of 
1:100. IgG4 positivity was defined as the presence of > 10 IgG4-positive plasma 
cells in at least one HPF at a magnification of x400. Response to treatment 
was defined as resolution or marked (> 50%) improvement of radiological, 
clinical and biochemical abnormalities, recurrence as reappearance of disease 
manifestations. Scoring systems were applied using data obtained during the 
initial evaluation period of six months. The onset of the initial evaluation period 
was defined as the presentation with major symptoms such as obstructive 
jaundice or overt pancreatic disease, prompting particular diagnostic activity. 
The clinical course of AIP may be protracted and highly variable, which may 
cause substantial diagnostic delay. Pancreatic resection because of presumed 
malignancy, although sometimes unavoidable, represents failure of timely 
diagnosis. None of the patients that underwent resection were operated later 
than six months after onset of jaundice or overt pancreatic disease. Therefore, 
data were used which were obtained during an initial evaluation period of six 
months, or until resection was performed.
One sample student t test and Fisher’s exact test were used to compare 
differences in means or frequencies. A two-sided p-value ≤ 0.05 was considered 
statistically significant. All authors had access to the study data, reviewed and 
approved the final manuscript.
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MEDICAL ETHICAL CONCERNS
The study was approved by the institutional review board of the Erasmus 
University Medical Center, Rotterdam, the Netherlands.
RESULTS
PATIENT CHARACTERISTICS AND CLINICAL PRESENTATION
A total of 114 patients were included (Table 1). The median age was 62 (IQR 
51 - 69) years, 99/114 (87%) were men. Females were diagnosed at a younger 
age than men (57, IQR 39 - 67 years, p < 0.001). Obstructive jaundice and 
signs of pancreatic exocrine insufficiency (weight loss and steatorrhea) were 
the most frequent presenting symptoms, followed by abdominal pain (usually 
mild discomfort) and recent onset diabetes (six months prior to diagnosis).
Other organ involvement (OOI) was present in two-thirds (78/114, 68%) 
of the patients. In two-thirds (52/78, 67%) of these patients one organ 
was affected, in one-third (26/78, 33%), multiple systems were involved. 
Usually, OOI coincides with or follows the pancreatic manifestation 
(34/78, 44%; 30/78, 38% respectively). In 18% (14/78) however, OOI was 
heralding AIP. Sclerosing cholangitis (65/105, 62% of all recorded OOI), 
was by far the most frequent extrapancreatic manifestation, followed 
by salivary gland involvement (Sjögren like syndrome, 9/105, 9%), 
retroperitoneal fibrosis (10/105, 10%), interstitial nephritis (5/105, 5%), 
localized or generalized lymphadenopathy (6/105, 6%), prostatitis 
(5/105, 5%), pulmonary involvement (4/105, 4%) and uveitis (1/105, 1%).
Elevated IgG4 (> 1.40 g/L) was present in 82% (85/104). Levels above 2.8 
g/L, which is the recommended level to discriminate between AIP and 
pancreatic cancer,10, 17 were present in 60% (62/104). The tumor marker 
Ca 19 - 9 was elevated (> 34 U/ml) in 58% (42/72). Levels above 300 U/ml, 
considered specific for pancreatic cancer,10, 18 were present in 18% (13/72). 
Autoantibodies (antinuclear antibody, rheumatoid factor, pANCA, anti lactoferrin 
or anticarbonic anhydrase II) were found in less than one-third of patients.
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Table 1 Baseline characteristics
Patients
n = 114
Percentage
%
Demographic findings
Male gender 99/114 87%
Age, median (IQR), y* 62 (51 - 69)
Male 62 (53 - 70)
Female 75 (39 - 67)
Presenting symptoms
Obstructive jaundice 87/114 76%
Abdominal pain 61/114 54%
Weight loss 98/111 88%
DM recent onset 40/113 35%
Steatorrhea 77/103 75%
Serological findings
IgG > 18.0 g/L 38/103 37%
IgG4 Median (IQR) g/L 5.01 (1.73 - 9.55)
Normal < 1.40 g/L 19/104 18%
> 1.40 g/L 85/104 82%
> 2.80 g/L 62/104 60%
Ca 19.9 > 34 U/ml 42/72 58%
> 100 U/ml 27/72 38%
> 300 U/ml 13/72 18%
Rheumatoid factor + 11/39 28%
Antinuclear antibody + 22/71 31%
Other antibody ∆ 8/64 13%
Other organ involvement
Presence None, n (%) 36/114 32%
Single, n (%) 52/114 46%
Multiple, n (%) 26/114 23%
Timing ¥ Preceding, n (%) 14/78 18%
Same time, n (%) 34/78 44%
Later, n (%) 30/78 38%
Prior treatment
Resection 18/114 16%
Exploratory surgery † 16/114 14%
Biliodigestive anastomosis 2/114 2%
Liver-kidney transplantation 1/114 1%
Chemoradiation 1/114 1%
Diagnostic delay
median (IQR), months‡ 4.3 (2.0 - 18.8)
IQR: inter quartile range, *Age at time of initial symptoms, ∆ pANCA, ALF or ACA-II , 
¥with respect to onset of jaundice or overt pancreatic disease, †explorative laparotomy, 
diagnostic laparoscopy, ‡time between date diagnosis and date symptoms
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RADIOLOGICAL FINDINGS
Radiological findings at initial clinical presentation are shown in Table 2. 
On computed tomogram (CT), diffuse swelling of the pancreas was present in 
56% (63/113), focal enlargement in 33% (37/113), of which 30% (34/113) in 
the head and 3% (3/113) in the tail. In 25% (28/113) there was no enlargement. 
Rim enhancement, an important criterion in the HISORt system, was present in 
24% (26/107). In 24% (27/113) regional adenopathy was noted, which could 
be misinterpreted as lymphatic metastases. In 24 patients (21%), abdominal 
CT showed no pancreatic abnormalities. Pancreatography (ERCP or MRCP) 
was performed in half of the patients (58/114, 51%). Diffuse stricturing of the 
main pancreatic duct was present in 66% (38/58), a segmental stricture in 17% 
(10/58). Ten percent (6/58) showed a normal pancreatogram. Biliary strictures 
Table 2 CT and MRCP/ERCP findings of AIP
Patients
n =114
Percentage
%
CT
Swelling of the pancreas:
Diffuse 63/113 56%
Segmental (head) 34/113 30%
Segmental (body) 0/113 0%
Segmental (tail) 3/113 3%
No enlargement 28/113 25%
Rim enhancement 26/107 24%
Pancreatic atrophy 6/113 5%
Pseudocyst 2/113 2%
Calcifications 1/113 1%
Regional adenopathy 27/113 24%
ERCP/MRCP
Pancreatic duct:
Normal 6/58 10%
Stricture diffuse 38/58 66%
Stricture segmental 10/58 17%
Biliary ducts:
Normal 3/97 3%
Stricture intrapancreatic 84/97 87%
Proximal (extrapancr) strictures 33/97 34%
Combined strictures 20/97 21%
CT: computed tomogram, ERCP: endoscopic retrograde cholangio-pancreatography, MRCP: 
magnetic resonance cholangio-pancreatography
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were very common, mostly strictures of the intrapancreatic part of the common 
bile duct (84/97, 87%). Proximal biliary strictures (proximal hepatocholedochal, 
hilar or intrahepatic) were present in 34% (33/97).
HISTOPATHOLOGICAL FINDINGS
Histology was available in 35/114 patients (31%), mainly from resection 
specimens (17/114, 15%) and exploratory surgery biopsy (11/114, 10%). 
A diagnosis of AIP was histologically confirmed in all of them. In only 
7/114 patients (6%) EUS fine needle biopsy (FNB) had been performed with 
lymphoplasmacytic sclerosing pancreatitis (LPSP) present in four and IgG4 
positivity in two. FNB contributed to diagnosis in only one patient. AIP type 2 
(reflected by idiopathic duct-centric pancreatitis IDCP), was diagnosed in 3/114 
patients (3% of the entire cohort), all of which underwent pancreatic resection.
THERAPY AND PROGNOSIS
Steroid therapy was started in 95/114 (83%), with an excellent response rate 
of 98% (92/94). Reasons to refrain from steroids (19/114, 17%) were: resection 
without postoperative recurrence (n=7), spontaneous remission or relatively mild 
symptoms (n=8), or patient refusal (n=2). One patient died of cardiovascular 
disease before therapy was initiated. Recurrence was noted in 37% (41/111);  
after remission without treatment in 17% (19/111), during treatment (failure 
to wean) in 11% (12/111) and after treatment in 9% (10/111). Death occurred 
in 14% (14/99). In 29% (4/14) of the deaths the cause was disease related 
(cholangitis / sepsis, hepatic or renal failure), 29% (4/14) cardiovascular and 36% 
(5/14) unknown. One case of malignancy was recorded (acute leukaemia).
PERFORMANCE OF DIAGNOSTIC SCORING SYSTEMS AND BASIS DIAGNOSIS
Twenty of 114 patients (18%) met the diagnostic criteria for all three 
systems, 40/114 (35%) met criteria for two systems and 33/114 (29%) for 
one system (Table 3). In 18% (21/114) all three scoring systems failed to 
confirm the diagnosis of AIP, even though these patients had an unchallenged 
clinical diagnosis of AIP based on postoperative histology, a combination of 
unexplained pancreatic disease, biliary disease/extrapancreatic manifestations 
and either response to steroids or IgG4-positive serology.
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The highest percentage of patients met the ICDC (77/114, 68%), followed by 
HISORt criteria (59/114, 52%, p=0.022) and Asian (37/114, 33%, p= 0.005, 
Table 4). The relatively poor performance of the Asian criteria in the entire 
cohort, was mainly due to a low percentage of diagnostic pancreatography in 
this series (58/114, 51%). If a pancreatogram was available, Asian, ICDC and 
HISORt criteria performed equally well (36/58, 62% vs 39/58, 67%, p=0.698 
and 31/58, 53%, p=0.452, respectively). If abdominal CT showed no pancreatic 
abnormalities (n=24, 21%), HISORt was the only scoring system that could 
establish a diagnosis of AIP (group C, which requires response to steroid 
Table 3 Basis on which diagnosis of AIP was confirmed
Percentage Patients no.
Criteria positive 82% 93/114
3x positive 18% 20/114
2x positive 35% 40/114
1x positive 29% 33/114
Criteria negative 18% 21/114
Histology 33% 7/21
Unexplained pancreatic disease
+biliary disease/OOI† + response to steroids
38% 8/21
Unexplained pancreatic disease + biliary 
disease/OOI + IgG4 positive
38% 8/21
†OOI: other organ involvement
Table 4 Performance of diagnostic scoring systems at initial presentation
Overall
n=114
Pancreatogram†
n=58
IgG4 negative 
n=19
Normal CT‡ 
n=24
Hisort 52% 53% 0% 50%
Group A 1% 0% 0% 0%
Group B 6% 12% 0% 0%
Group C 45% 41% 0% 50%
Asian 33% 62% 42% 0%
ICDC 68% 67% 58% 0%
AIP type 1 definitive 60% 55% 26% 0%
AIP type 1 probable 2% 0% 0% 0%
AIP type 2 definitive 0% 0% 0% 0%
AIP type 2 probable 0% 0% 0% 0%
AIP n.o.s. 6% 12% 32% 0%
† Pancreatogram present ,‡normal appearance of pancreas on computed tomogram. 
Systems were scored with initial clinical findings, e.i. EUS FNA was included, histology 
obtained by resection or laparotomy biopsy was excluded
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therapy). If IgG4 levels were normal (19/104, 18%), AIP was never diagnosed 
according to the HISORt criteria, while the Asian criteria and ICDC established 
the diagnosis in 42% (8/19) and 58% (11/19), respectively (p=0.517).
DISCUSSION
In this well-characterized cohort of AIP patients, the three major diagnostic 
criteria systems proved complementary rather than overlapping. At initial 
clinical presentation, the majority of patients with AIP was correctly identified 
by any of the three systems, without the need for histology. Our data further 
suggest that a small subset of patients does not meet the criteria of any of 
these systems. Therefore, these scores are valuable and helpful, particularly 
for defining populations, but should not be regarded as absolute, gold 
diagnostic standard. Based on our data and the clinical applicability of the 
respective systems, we recommend the use of HISORt criteria, and the Asian 
criteria if a pancreatogram is available (optional) or if IgG4 levels are normal 
(mandatory). If diagnosis is still not confirmed, the ICDC can be used.
In our opinion, the intrinsic erratic nature of AIP, with its protracted and 
highly variable clinical course, forms the main drawback in the clinical 
applicability of any diagnostic criteria system in a given moment of the 
disease. Radiological, clinical and biochemical abnormalities may fluctuate 
in time. The 18% of patients in our cohort that did not meet any of these 
systems in the initial evaluation period, had a firm diagnosis of AIP. It was 
only a matter of timing, pancreatic resection or steroid trial, to finally 
make the diagnosis. The main differential diagnosis with malignancy 
however, prompts the clinician to minimize diagnostic delay. We believe 
it is highly unlikely that any diagnostic criteria system will totally cover 
this dilemma in a given short period of time with sufficient specificity.
In general, our series resembles other large cohorts of AIP patients.10, 19-22 
Since there were only three cases of histologically confirmed IDCP (type 2 
AIP), our cohort reflects mainly the clinical spectrum of LPSP (type 1 
AIP). Differences in disease characteristics between various cohorts are 
probably due to differences in the use of diagnostic criteria systems and 
their ability to differentiate between type 1 and type 2 AIP.2-3 The Asian 
criteria and HISORt in particular highlight the features of AIP type 1. Italian6 
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and German criteria11 appear to be targeted at both types. Whether the 
good performance of the HISORt criteria in our cohort reflects selection 
bias or true low incidence of type 2 AIP in the Netherlands is not clear.
We report a high percentage of elevated Ca 19 - 9 levels in 58% of cases 
compared to an average of 25% in other series.6, 10, 21 Levels above 300 U/
ml, considered specific for pancreatic cancer,10, 18 were present in 18%. This is 
not explained by a difference in the presence of proximal biliary involvement, 
which was similar (34%). We report five cases of AIP associated prostatitis, 
which is quite uncommon. No case of inflammatory bowel disease was noted, 
corresponding with virtual absence of type 2 AIP. Response and recurrence rates 
(98% and 37% respectively) match those reported in the literature.
To our knowledge, this is the first study that uses a well-defined cohort 
of AIP patients to head-to-head test the dominant and currently available 
diagnostic criteria systems for AIP. The strengths of our study include the large 
number of patients and the use of data at initial clinical presentation, which 
provides insight in the respective performance of these systems in common 
gastroenterology practice. Furthermore we provide specific clues for certain 
difficult diagnostic situations such as a normal CT (which was present in 21% of 
our cohort) and normal IgG4 levels (which were reported in 18%). One limitation 
of the current study is the retrospective nature and the use of HISORt and 
Asian criteria (that particularly highlight type 1), which might have introduced 
selection bias. Another limitation is the limited availability of pancreatic core 
biopsies, as they are only rarely obtained in the Netherlands. In only one of 
seven patients that underwent EUS fine needle biopsy (FNB) in our cohort did 
this contribute to diagnosis. Although the technique is increasingly feasible 
due to the development of flexible large bore EUS needles, the required 
histological expertise is not commonplace. This impairs a proper evaluation 
of its contribution to the diagnostic process in patients suspected of having 
AIP. However, the crucial role of EUS FNA (or FNB) in the diagnostic process 
of a pancreatic mass remains undisputed. Response to steroid therapy as a 
diagnostic tool to confirm AIP should only be used if malignancy is properly 
excluded,10 that is by an attempt to confirm malignancy by tissue sampling. 
A final limitation in our study is the observer bias that might have been 
introduced in the radiological revisions. Only the radiologist was blinded for 
the diagnosis. In daily practice, pancreatic enlargement and rim enhancement 
can be quite subtle. The quality of pancreatograms and cholangiograms varies 
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considerably and they may be difficult to evaluate. The detection of the subtle 
changes associated with AIP are enhanced by knowledge and training,23 which 
was likely to be the case in the revisions of the pancreatologists and research 
fellows.
With this study, no conclusions can be made regarding the specificity of the 
diagnostic scoring systems, i.e. false positivity in differential diagnosis with 
malignancy or chronic pancreatitis. Reports on diagnostic scoring systems 
generally focus on capability of classifying the presence of disease. With each 
scoring system, corresponding diagnostic algorithms for differential diagnosis 
with malignancy were developed.9-10, 24-25 Extensive validation studies of all 
diagnostic criteria simultaneously are not reported yet. Because of the rarity 
of the disease, uniformity and international consensus should be pursued. 
The development of the international consensus diagnostic criteria was an 
important step as it combined several good aspects of various scoring systems. 
They are excellent for research purposes, but in our opinion their clinical use is 
limited because of their complexity. An international prospective trial, aimed at 
the optimal diagnostic algorithm for the diagnosis of AIP, is highly desirable.
In conclusion, our data show that at initial clinical presentation, the majority of 
patients with AIP was correctly identified by any of the three major diagnostic 
criteria systems, without the need for histology. The systems proved to be 
complementary rather than overlapping. A small subset of patients did not 
fulfil the criteria of any of these systems. Though very useful in defining 
populations and confirming diagnosis of AIP, they should not be regarded as 
absolute, gold diagnostic standard. In daily practice, we recommend the use 
of HISORt criteria, and the Asian diagnostic scoring system if a pancreatogram 
is available (optional) or if IgG4 level is normal (mandatory). If diagnosis is still 
not confirmed, the ICDC can be used.
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ABSTRACT
Background Occasionally patients undergoing resection for presumed 
malignancy of the pancreatic head are diagnosed with benign disease 
postoperatively. Autoimmune pancreatitis (AIP) is a rare disease that mimics 
pancreatic cancer. We aimed to determine the prevalence of benign disease 
and AIP in patients who underwent pancreatoduodenectomy (PD) over a 9 year 
period, and to explore if and how surgery could have been avoided. 
Methods All patients undergoing PD between 2000 and 2009 in a tertiary 
referral centre were analyzed retrospectively. In cancer-negative cases, 
postoperative diagnosis was reassessed. Preoperative index of suspicion of 
malignancy was scored as non-specific, suggestive or high. In AIP patients 
diagnostic criteria systems were checked. 
Results 274 PDs were performed for presumed malignancy. The prevalence 
of benign disease was 8.4%, overall prevalence of AIP was 2.6%. Based on 
preoperative index of suspicion of malignancy, surgery could have been 
avoided in 3 non- AIP patients. All AIP patients had sufficient index to justify 
surgery. If diagnostic criteria would have been checked however, surgery could 
have been avoided in one to five AIP patients. 
Conclusions The prevalence of benign disease in patients who underwent 
PD for presumed malignancy was 8.4%, nearly one third attributable to 
AIP. Although misdiagnosis of AIP as carcinoma is a problem of limited 
quantitative importance, every effort to establish the correct diagnosis 
should be undertaken considering the major therapeutic consequences. 
IgG4 measurement and systematic use of diagnostic criteria systems are 
recommended for every candidate patient for PD when there is no histological 
proof of malignancy.
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INTRODUCTION
Nowadays, routine work up consists of CT scan, frequently combined with 
endoscopic ultrasonography (EUS) and fine needle aspiration (FNA) cytology. 
Although the sensitivity of EUS with FNA is approximately 80% and the 
specificity of positive cytology approaches 100%,1 false negative results are 
common and the negative predictive value of these tests is low.2 Therefore, 
if a person presents with a mass in the pancreatic head without metastases, 
a PD will usually be considered as it is the only curative option. Five to 11% 
of patients however are found to have a benign disease on postoperative 
histological examination.3-8 In large volume centers the mortality of this 
operation is less than 5%9 and morbidity is substantial 46%.4
Autoimmune pancreatitis (AIP) is a rare disease that may present with a 
pancreatic head mass, jaundice and weight loss, and thus may mimic pancreatic 
carcinoma clinically. Biliary involvement (distal and proximal) is common, 
sometimes without overt pancreatic disease, mimicking cholangiocarcinoma. 
The disease is highly responsive to steroids,10 and this feature can be used 
as a diagnostic tool.11 The exact pathogenesis is unknown. In 68 to 95% 
of patients IgG4 serum levels are elevated.12-16 AIP can be associated with 
extrapancreatobiliary manifestations like retroperitoneal fibrosis, Sjögren’s 
disease, rheumatoid arthritis, inflammatory bowel disease, interstitial nephritis, 
thyroïditis or inflammatory tumors in lungs, mediastinum or liver. According 
to several large retrospective series, 23 to 38% of benign PDs are due to 
autoimmune pancreatitis.3-4 Increasing knowledge and awareness of this 
intriguing disease is expected to avoid unnecessary surgery in a substantial 
amount of patients. Unfortunately there is no single diagnostic test. Several 
diagnostic criteria systems of AIP have been proposed including the HISORt and 
Asian criteria.17-18 The aims of this study were first to determine the prevalence 
of benign disease and in particular of AIP in patients who underwent PD for 
presumed malignancy in the past decade, second to investigate if there was any 
decline in misdiagnosis over time, and third to assess if and how unnecessary 
surgery possibly could have been avoided.
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METHODS
STUDY POPULATION
All patients undergoing PD between January 1 2000 and January 31 2009 in a 
tertiary referral center with multidisciplinary approach to pancreatic and biliary 
disease were retrospectively analyzed. Patients were included if the indication 
for surgery was suspicion of malignancy in the pancreatic head. If postoperative 
diagnosis did not harbor a benign or malignant neoplasm it was classified as 
a benign PD. Demographic characteristics (age, gender and mortality) were 
evaluated in all patients. In benign PDs postoperative diagnosis was reassessed 
by revision of histological and clinical data.
The following clinical data were extracted from patient case records: age, 
gender, diabetes mellitus, history of chronic pancreatitis, autoimmune disease, 
smoking, alcohol consumption, jaundice, weight loss and pain. Laboratory 
results of bilirubin, Ca19 - 9, total IgG, IgG4, and autoantibodies (RF, ANF) 
were recorded. Relevant radiological and endoscopic studies (ultrasound US, 
computed tomography CT, magnetic resonance imaging MRI, endoscopic 
retrograde cholangio pancreatography ERCP, endoscopic ultrasound EUS) were 
reviewed. Based on these data and -if available- preoperative cytological or 
histological examination, a preoperative index of suspicion of malignancy (non-
specific, suggestive, highly suspicious)6 was calculated (detailed information 
in Addendum Table 3). Van Gulik et al described this system in 1999, using 
US and ERCP features of malignant and inflammatory lesions in the pancreatic 
head. We added clinical symptoms (weight loss, jaundice and pain), level of 
Ca19 - 9,19 EUS features8 and pathology findings (preoperative histology or 
cytology). For each examination, suspicion of cancer was scored on a 0/+/++ 
scale. Retrospectively, surgery was considered unnecessary when preoperative 
findings were non-specific. In AIP patients, the HISORt and Asian diagnostic 
criteria systems (Addendum Table 4) were applied on preoperative data, to 
determine if and how surgery could have been avoided.
HISTOPATHOLOGIC EVALUATION
Resection specimens were revised by two expert pathologists familiar with 
pancreatic disease and with special interest in AIP. Immunostaining for IgG4 was 
performed using a monoclonal mouse anti-human IgG4 (Zymed Laboratories, 
San Francisco, USA), with a working dilution of 1:100. The presence of > 10 
39
IgG4-positive plasma cells in at least one HPF at a magnification of x400 was 
considered suggestive of AIP. Each specimen was evaluated for the presence of 
microscopic AIP features, as previously established in several series of resection 
specimens.20-27 A classical histological triade is recognized in 80%: dense 
lymphoplasmacytic infiltration, cuff like periductal fibrosis and obliterative 
phlebitis (venulitis). Other common features are: perineural inflammation, 
acinar atrophy or fibrosis, storiform (spindle shaped) fibrosis, granulomas 
and the presence of neutrophils and eosinophils. More recently, two subtypes 
of autoimmune pancreatitis have been distinguished, each with a distinct 
clinical and histopathological picture: the predominant lobular type (AIP-PL or 
type 1) and predominant ductal type (AIP-PD, type 2).21 AIP type 1 represents 
the “classic” lymphoplasmacytic sclerosing pancreatitis, more prevalent in 
older men, and is strongly associated with retroperitoneal fibrosis and biliary 
strictures, the latter often becoming prominent after pancreaticoduodenectomy. 
Especially this type of AIP is associated with an elevated serum IgG4 and the 
presence of IgG4 positive plasma cells in tissue. The less well-known AIP type 2 
is characterized by the presence of so-called GELs: granulocytic epithelial 
lesions, which represent destruction of of pancreatic interlobular ductal 
epithelium.26 This subtype is more prevalent in younger patients, more often 
associated with ulcerative colitis or Crohn’s disease and generally shows no 
recurrence after resection. It is less associated with increase of IgG4. While AIP 
type 1 usually presents with typical histological pattern, AIP type 2 could be 
more difficult to diagnose, both preoperatively on biopsy material as well as on 
resection specimens. The typical fibrosis is missing and IgG4 staining is less 
useful.20-27
Suggestive of other forms of chronic pancreatitis are pseudocysts and 
calcifications, irregular ductal dilation, mucoprotein plugs and necrosis 
(suggestive of chronic alcoholic or obstructive pancreatitis), pancreas divisum 
or inflammation of the duodenal wall (groove pancreatitis).3
STATISTICAL ANALYSIS
Chi square and unpaired t-test were used to compare gender and age between 
malignant and benign postoperative diagnosis. Fischer’s exact test and unpaired 
t-test were used to compare differences in characteristics and symptoms of 
patients with benign pancreatoduodenectomies. Two tailed p values of < 0.05 
were considered statistically significant.
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RESULTS
Of 288 pancreatoduodenectomies performed during 2000 - 2009, 274 were 
performed for presumed malignancy. Twenty-three (8.4%) of 274 resections 
were negative for neoplastic disease (Figure 1). Patients with malignancy 
were significantly older (mean 63.7 ± 10.1) than those with benign disease 
(mean 58.6 ± 12.7) (p = 0.004). There was no difference in gender (p= 0.832). 
Overall operative mortality was 20/288 (6.9%) but mortality was not observed 
in the benign PD cases. Mortality did not differ between the first and second 
half of the study period (7.1% versus 6.8%, p = 1.0).
In Table 1 postoperative diagnoses of 23 benign PDs are summarized. 
AIP was diagnosed in 30.4%, that is 2.6% of total PDs performed for presumed 
malignancy. Clinical characteristics and symptoms of benign PDs (AIP and non 
AIP) are summarized in Table 2. No statistical differences were noted between 
AIP and non AIP except for pre-operative presence of diabetes mellitus, being 
more frequent in AIP patients (71% versus 19%, p = 0.026).
The prevalence of misdiagnosis in the first and second half of the study period 
showed a decline from 10.9% to 5.8% but it failed to gain statistical significance 
pancreatitis have been distinguished, each with a distinct
clinical and histopathological picture: the predominant
lobular type (AIP-PL or type 1) and the predominant ductal
type (AIP-PD, type 2) [21]. AIP type 1 represents the
‘‘classic’’ lymphoplasmacytic sclerosing pancreatitis, more
prevalent in older men, and is str ngly associated with
retroperitoneal fibrosis and biliary strictures, the latter often
becoming prominent after pancreaticoduodenectomy.
Especially, this type of AIP is associated with an elevated
serum IgG4 and the pr sence of IgG4 positive plasma cells
in tissue. The less well-known AIP type 2 is characterized
by the presence of so-called GELs: granulocytic epithelial
lesions, which represent destruction of pancreatic inter-
lobular ductal epithelium [26]. This subtype is more pre-
valent in younger patients, more often associated with
ulcerative colitis or Crohn’s disease and generally shows
no recurrence after resection. It is less associated with
increase of IgG4. While AIP type 1 usually presents with
typical histological pattern, AIP type 2 could be more
difficult to diagnose, both preoperatively on biopsy mate-
rial as well as on resection specimens. The typical fibrosis
is missing and IgG4 staining is less useful [20–27].
Suggestive of other forms of chronic pancreatitis are
pseudocysts and calcifications, irregular ductal dilation,
mucoprotein plugs, and necrosis (suggestive of chronic
alcoholic or obstructive pancreatitis), pancreas divi-
sum, or inflammation of the duodenal wall (groove
pancreatitis) [3].
Statistical analysis
Chi square and unpaired t test were used to compare gender
and age between malignant and benign postoperative
diagnosis. Fischer’s exact test and unpaired t test were used
to compare differences in characteristics and symptoms of
patients with benign pancreatoduodenectomies. Two-tailed
p values of\0.05 were considered statistically significant.
Results
Of 288 pancreatoduodenectomies performed during
2000–2009, 274 were performed for presumed malignancy.
Twenty-three (8.4 %) of 274 resections were negative for
Fig. 1 Flow chart of patient
inclusion
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(p = 0.19). The proportion AIP among misdiagnosed patients remained constant 
(26.7% versus 37.5%, p = 0.66).
Based on the preoperative index of suspicion of malignancy (Table 3), 
postulating that for surgery findings should at least be suggestive, resection 
could have been avoided in three non AIP patients, one with alcoholic and two 
with obstructive chronic pancreatitis. The index of suspicion in these cases 
was non-specific. Radiology was indicative of chronic pancreatitis without 
clear signs of malignancy. The decision to operate was mainly based on 
symptoms (suggestive n=2 or non-specific n=1). The index of suspicion was 
Table 1 Clinicopathologic classification of disease in 23 benign pancreatoduodenectomies
No of patients (%)
Chronic pancreatitis
Alcoholic 3 (13.0%)
Obstructive 7 (30.4%)
Idiopathic 3 (13.0%)
Autoimmune 6 (26.1%)
Biliary tract disease
Autoimmune 1 (4.3%)
Idiopathic 1 (4.3%)
Papillary fibrosis 1 (4.3%)
Crohn’s disease (infiltrate) 1 (4.3%)
Table 2 Characteristics and symptoms of patients with benign pancreatoduodenectomy
AIP Non AIP P value
No. 7 16
M:F ratio 6.0 2.2 0.62
Mean age years (± SD) 53 (± 19.7) 54 (± 7.9) 0.65
Diabetes (de novo) 5 (2) (71%) 3 (2) (19%) 0.03
History of chronic pancreatitis 0 2 (13%) 1.00
Autoimmune disease 2 (29%) 1 (6%) 0.21
Smoking 5 (71%) 9 (56%) 0.66
Alcohol > 2 U daily 1 (14%) 8 (50%) 0.18
Jaundice 6 (86%) 7 (44%) 1.00
Mean weight loss kg (± SD) 2.7 (± 5.6) 7.0 (± 7.7) 0.21
Pain - none / mild 5 (71%) 10 (63%) 1.00
- moderate/severe 2 (29%) 6 (37%) 1.00
Fisher’s exact and unpaired t-test. SD = standard deviation.
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also non-specific in another case finally diagnosed with Crohn’s disease, but 
surgery could possibly not have been avoided since a tumor-like mass was 
found infiltrating both pancreas and colon ascendens and causing obstructive 
symptoms. The index of suspicion in all seven patients with AIP was sufficient 
to justify the operation (suggestive n=4; strong suspicion n=3). Important 
reasons to operate were marked elevation of Ca19 - 9 (levels as high as 23 
284 kU/l), suggestive imaging (mass on EUS, double duct sign on CT/MRI or 
ERCP, regional adenopathy on CT or MRI) and (false) positive cytology (EUS-
FNA). Based on diagnostic criteria systems for AIP however (Table 4), surgery 
could have been avoided in at least one case. This patient developed biliary 
strictures postoperatively, triggering clinicians to consider AIP. The preoperative 
IgG4 level (measured retrospectively) was very high (13.6 g/l). Based on 
the spectacular response to steroids postoperatively it is very likely that 
steroids would have prevented the operation. In four patients, findings at 
pancreatography and / or elevated IgG4 levels would have justified a steroid 
trial. However, none of the patients had an adequate pancreatogram and in 
only one case IgG4 had been measured preoperatively. In two AIP patients 
surgery seemed inevitable also in retrospect. Even if responsive to steroids, 
criteria would not be met (no other criterion present, IgG4 normal). In summary, 
surgery could have been avoided in at least 4 (which would reduce the 
percentage benign PDs to 6.9), but possibly 8 patients (three non AIP and five 
AIP) according to the index of suspicion for malignancy and the HISORt criteria. 
The pre-operative work-up in AIP patients was unsatisfactory.
DISCUSSION
The prevalence of benign disease in patients who underwent PD for presumed 
malignancy in our center was 8.4%. During a 9-year period seven patients were 
post-operatively diagnosed with AIP, corresponding with a total prevalence 
in this population of 2.6% and accounting for nearly one third of all benign 
cases. These findings show that AIP accounts for a significant proportion of 
incorrect preoperative diagnoses, but also indicate that, from a quantitative 
perspective, missing the diagnosis of AIP was a problem of limited magnitude. 
In our national AIP database, containing 130 patients, 20% underwent resection 
for presumed malignancy (unpublished data). Our data are compatible with 
other large series, reporting 5 to 11% 3-8 benign disease in patients after PD 
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for suspected malignancy, with AIP constituting 23 to 38% of benign cases.3-4 
The prevalence declined over time although this was not statistically significant.
A preoperative diagnosis of AIP was missed for several reasons. First we 
noted insufficient preoperative work up in patients finally diagnosed with AIP. 
IgG4 measurements were missing in 6/7 cases and adequate imaging of the 
pancreatic duct was not performed in any patient, both being crucial elements 
in either the American (HISORt) or Asian diagnostic strategy.28 Second, the 
importance of Ca19 - 9 was overestimated. Levels of > 300 U/ml are thought 
to be pathognomonic for malignancy19 but markedly elevated levels were 
found in 2 of our AIP patients. The third reason is the mere fact that in some 
patients it may be virtually impossible to detect the disease without resecting 
the pancreas. In a recent study, in which a diagnostic strategy to distinguish 
AIP from pancreatic cancer based on HISORt criteria was tested, researchers 
from the US found that sensitivity of diagnostic criteria is 70%. In 30% of AIP 
cases however, the diagnosis could not be confirmed without a steroid trial, 
pancreatic core biopsy or surgical resection.29
Based on the index of suspicion of malignancy we used in this study, 3 non 
AIP patients underwent PD while the index was non-specific. Nowadays, we 
believe that the index should at least be suggestive before embarking on 
surgery. Although seemingly easy to use, this index is subject to personal 
interpretation, and discussion about findings to be interpreted as “suggestive” 
or “very suspicious” is inevitable. To better define the clinical usefulness of the 
index prospective validation studies are needed. Noteworthy, applying this 
index illustrated the fact that in patients with AIP findings may clearly suggest 
malignancy. Unnecessary surgery can be avoided only if this diagnosis is always 
considered and actively pursued.
Diagnosing AIP may be troublesome. The two main diagnostic systems (HISORt 
and Asian diagnostic criteria) are based on specific combinations of radiological 
(focal enlargement, sausage shaped pancreas with hypodense rim, diffuse 
or segmental narrowing of the pancreatic duct), serological (IgG4, IgG and 
the presence of autoantibodies like RF or ANA), and histological (pancreatic 
and or extrapancreatic tissue) findings, and the response to steroid therapy. 
An extensive discussion of the diagnostic criteria is beyond the scope of this 
article, but in preoperative work up the following clues are of key importance 
and should be looked for in every patient: elevated IgG4, narrowing of the 
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pancreatic duct (in contrast with ordinary carcinoma patient who usually 
presents with double duct sign) and evidence of extrapancreatobiliary 
involvement.
In our opinion a diagnostic strategy of measuring serum IgG4 levels in all 
patients suspected of pancreatic or cholangiocarcinoma could well be considered. 
Of all patients referred for presumed malignancy, 20% are candidates for surgery. 
With a prevalence of 2.5% among those undergoing PD, 200 patients would need 
to be screened to detect one case of AIP eligible for surgery. At approximately 
$50 per test, $10 000 would be spent for each patient preoperatively 
diagnosed with AIP, an amount considerably less than the costs of surgery 
and its associated morbidity (about $30 000).2, 30 In resection for presumed 
hilar cholangiocarcinoma the percentage autoimmune cholangitis is probably 
higher (1.1 - 8.1%)31 and less patients would need to be screened. In our center, 
with an annual volume of approximately 30 PDs, and taken into account that 
sensitivity of IgG4 is 68% to 95%,12-16 it would take at least one and a half year 
of routine screening to detect one patient with AIP. Although this may seem a 
low yield of this screening strategy, this approach may still be defendable and 
worthwhile in the light of possible unnecessary major surgery, morbidity and 
mortality. This strategy would also allow to detect patients with AIP considered 
to have irresectable malignancies because of infiltration, lymphadenopathy or 
supposed metastases. This group is easily forgotten but not less important or 
tragic: be diagnosed with incurable cancer while steroids can heal. Although 
routine IgG4 measurement preoperatively has been gradually introduced in 
our center since 2006, we have not been able to prevent the one case that was 
diagnosed postoperatively after 2006. This young female with preoperative 
normal IgG4 and a cytology report of malignancy on EUS-FNA, was diagnosed 
with AIP type 2. It is only recently that AIP type 2 is acknowledged as a distinct 
phenotype. It is more difficult to detect because IgG4 is often not elevated 
and patient characteristics are very different from the classical jaundiced old 
man with weight loss and retroperitoneal fibrosis. This case reflects the lacuna 
in current diagnostic strategies, especially in IgG4 negative disease. Another 
important aspect and limitation of measuring IgG4 is that levels up to 2 times 
the upper limit of normal can also be found in patients with pancreatic cancer, 
primary sclerosing cholangitis and other pancreatic disease. The specificity of in 
particular slightly elevated levels is limited.12-16, 32 If a cut off value is used of > 2.8 
g/L however, specificity rises to 98%.29
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The second tool to detect AIP preoperatively is histology. In contrast to 
Asian criteria, the HISORt already diagnoses AIP if only histology is positive. 
This gives pancreatic core biopsy a special significance. Obviously, reliable 
histological assessment requires a dedicated pathologist, who is familiar with 
the histological features of pancreatic disease and IgG4 immunostaining. 
AIP can usually be diagnosed in resection specimens without great difficulty and 
be distinguished clearly from other types of pancreatitis and adenocarcinoma. 
IgG4 immunostaining however has limited sensitivity and specificity and shows 
overlaps between AIP, chronic pancreatitis and adenocarcinoma. Deshpande 
et al showed that IgG4 positive cells were identified in resection specimens in 
42.9% cases of chronic pancreatitis and 52.6% cases of adenocarcinoma (using a 
working dilution of 1:50, scored in a 20x field). These findings suggest limited 
diagnostic value of pancreatic biopsy.21 Data regarding the role of pancreatic 
biopsy, however, are sparse and disputed. Detlefsen et al33 recognized AIP in 
pancreatic core biopsies using six microscopic features (granulocytic epithelial 
lesions -GELs-, > 10 IgG4-positive per high power field -HPF- , > 10 eosinophilic 
granulocytes/HPF, cellular fibrosis with inflammation, lymphoplasmacytic 
infiltration and venulitis). They were able to detect AIP in 76% when they used 
a cut off level of four features, rising to 86% when cases were added with 
three features including GELs. In this study there was no control group with 
adenocarcinoma. The Mayo Clinic group was able to detect AIP in EUS guided 
true cut biopsies in 100%.34 Further studies are required to further establish the 
diagnostic significance of pancreatic biopsy in patients possibly suffering from 
AIP.
The third major diagnostic tool is pancreatography. Preoperative ultrasound 
and/or or CT showing a non-dilated pancreatic duct should always give rise to 
suspect AIP and not cancer. When MRI is performed, MRCP should be performed 
as well. Although a recently published randomized controlled trial showed that 
in carcinoma of the pancreatic head early surgery is superior to preoperative 
biliary drainage, most patients will still undergo an ERCP before surgery.35 While 
gastroenterologists usually will not try to deliberately cannulate and fill the 
pancreatic duct, adequate pancreatography is helpful in establishing the correct 
diagnosis.
Finally, a two-week trial of corticosteroids11 can confirm the diagnosis, but this 
should only be considered if other findings clearly suggest the possibility of AIP. 
We believe it is an important tool but should be left in experienced hands and 
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only after careful multidisciplinary review of all relevant data. Malignant tumors 
as well as benign non-autoimmune mediated inflammatory processes may 
respond to steroids to some degree and victims of the autoimmune hype have 
already been reported.36
CONCLUSIONS
Prevalence of benign disease in patients who underwent 
pancreatoduodenectomy for presumed malignancy is 8.4%. One third of 
these cases are diagnosed with AIP. In nine years the prevalence of benign 
PDs showed a non significant trend towards decline from 10.9% to 5.8%. 
The proportion AIP remained stable, at least partially due to insufficient 
preoperative work up. Routine work up for pancreatic cancer is not enough to 
detect these patients beforehand. IgG4 measurement and systematic use of 
diagnostic criteria systems should be considered in every patient eligible for PD 
but without preoperative histological confirmation of malignancy.
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ADDENDUM MATERIAL
Addendum Table 3 Index of suspicion of malignancy6
Non specific Suggestive Strong suspicion
Clinical 
symptoms
Weight loss< 5kg Jaundice > 10kg weight loss
Mild to moderate pain 
alone
+/- severe pain
Ca 19.9 < 34 kU/l = normal > 34 and < 300 kU/l ≥ 300 kU/l
Preoperative 
cytology or 
histology
Benign Atypical Malignant
Imaging Non specific
Sugg chronic 
pancreatitis
Suggestive neoplasm
US, CT, MRI Mass (solid / cystic) Calcifications, 
pseudocyst
Double duct dilation
Focal enlargement Parenchymal atrophy Blunt stenosis CBD or PD 
stenosis
Single duct dilation Tapering stenosis PD 
or CBD
Abnormal portal venous 
Doppler / encasement
Thickening CBD wall Diffuse 
enlargement / rim
Regional adenopathy
PD irregularities Infiltration
ERCP Single duct dilation CBD stenosis long, 
tapered, smooth
CBD stenosis (short, 
irregular, shouldering, 
excentric, complete)
PD stenosis multiple, 
short, side branches
PD stenosis (single, 
> 1cm, irregular, no side 
branche)
Double duct sign
Endoscopic US Single duct dilatation Parenchymal / ductal 
criteria
Mass
Thickening CBD wall Lymphadenopathy
Vascular involvement
PD: pancreatic duct, CBD: common bile duct
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Addendum Table 4 HISORT and Asian Diagnostic Criteria (summarized)17,18
Criterion
Histology Lymphoplasmacytic sclerosing pancreatitis 
and
> 10 IgG4 positive plasmacells / high power 
field
Imaging Typical Diffusely enlarged pancreas with rim
Diffusely irregular pancreatic duct (PD)
Other Focal mass or enlargement, focal PD stricture
Atrophy, calcification, pancreatitis
Serology IgG4 > 1.40 g/L Asian: IgG > 17.0 g/L, presence of 
autoantibodies (ANA, RF)
Other Organ involvement Biliary strictures, salivary glands, mediastinal 
lymphadenopathy, retroperitoneal fibrosis
Response to steroid therapy
In HISORt criteria system diagnosis is made either if histology alone is positive (resection 
or pancreatic core biopsy), or if combination typical imaging and elevated IgG4, or if 
unexplained pancreatic disease with elevated IgG4 or other organ involvement and 
response to steroids. In Asian criteria typical imaging is mandatory either in combination 
with serology (IgG4, IgG and RF or ANA) or histology of pancreatic biopsy lesions or 
histology alone if ipositive in resected pancreas. Response to steroids is conducted only if 
typical imaging is present and after negative work up for pancreatic cancer. Other organ 
involvement is not included in Asian criteria.
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ABSTRACT
Background & aims Autoimmune pancreatitis (AIP) is often difficult to 
distinguish from pancreatic carcinoma or other pancreatobiliary diseases. 
Patients with malignancies are frequently identified based on high serum 
levels of carbohydrate antigen 19 - 9 (Ca 19 - 9), whereas high levels of 
immunoglobulin (Ig)G4 (> 1.4 g/L) are characteristic of AIP. We investigated 
whether serum levels of these proteins can differentiate between patients with 
these diseases. 
Methods We measured levels of Ca 19 - 9 and IgG4 in serum samples 
from 33 patients with AIP, 53 with pancreatic carcinoma, and 145 with 
other pancreatobiliary disorders. Ca 19 - 9 was measured using an 
electrochemiluminescense immunoassay and IgG4 was measured using the 
Peliclass IgG subclass nephelometry kit. We associated protein levels with 
patient diagnoses and determined cut-off levels for each assay. Logistic 
regression analysis was used to evaluate combined data on Ca 19 - 9, IgG4, 
and bilirubin levels. 
Results Low levels of Ca 19 - 9 were independently associated with AIP, 
compared with pancreatic adenocarcinoma (odds ratio [OR], 0.28; 95% 
confidence interval [CI], 0.13 - 0.59; P=.0001). Using an upper level of 74 U/ml, 
the assay for Ca 19 - 9 identified patients with AIP with 73% sensitivity and 74% 
specificity. Using a lower level of 2.6 g/L, the assay for IgG4 identified these 
patients with 70% sensitivity and 100% specificity. Levels of IgG4 ranging from 
1.4 to 2.6 g/L identified AIP patients with higher sensitivity (85%) but lower 
specificity (81%). Combining data, levels of Ca 19 - 9 < 74 U/ml and IgG4 > 1.0 
g/L identified patients with AIP with 94% sensitivity and 100% specificity. 
Conclusions Patients with AIP have lower levels of Ca 19 - 9 than those with 
pancreatic carcinoma. Measurement of either Ca 19 - 9 or IgG4 level alone 
are not accurate for diagnosis. However, the combination of Ca 19 - 9 levels 
< 74 U/ml and IgG4 > 1.0 g/L distinguish patients with AIP from those with 
pancreatic carcinoma with 94% sensitivity and 100% specificity.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is a rare, distinct condition that often presents 
with a pancreatic mass, jaundice and weight loss, and thus may mimic 
pancreatic carcinoma. In a recent study, we described a 2.6% prevalence of AIP 
in patients undergoing pancreatoduodenectomy for presumed malignancy of 
the pancreatic head.1 Biliary involvement is common in AIP, sometimes without 
overt pancreatic disease, and can be confused with cholangiocarcinoma or 
primary sclerosing cholangitis (PSC). Frequently AIP represents the pancreatic 
manifestation of IgG4-related disease, a systemic disorder that may not 
only involve the pancreas but almost any other organ. AIP can be associated 
with disorders such as retroperitoneal fibrosis, sialadenitis, prostatitis, 
interstitial nephritis and inflammatory tumours in lungs, mediastinum or liver. 
The disease is highly responsive to steroids2 , a characteristic which can be 
helpful in establishing the diagnosis.3 There is no single diagnostic test that 
reliably differentiates AIP from other disorders. IgG4 is the best single test to 
distinguish between AIP and malignancy, with an optimal cut-off level of 2.8 
g/L (twice the upper limit of normal), yielding sensitivity of 65% and specificity 
of 98%.4 Levels up to 2.8 g/L can also be found in patients with pancreatic 
carcinoma, PSC and other pancreatic disorders. Thereby, the specificity of 
slightly elevated levels is limited.4-9 Several other serological markers - total IgG 
or autoantibodies like antinuclear antibody, rheumatoid factor, anti carbonic 
anhydrase II and antilactoferrin - have been proposed as useful diagnostic 
tests.10 However, most of the studies describing the value of these tests lack 
sufficient validation.
Ca 19 - 9 is a tumor associated antigen originally isolated from a human 
colorectal cancer cell line. The level is elevated in the majority of pancreatic 
carcinoma patients but it lacks diagnostic performance required for early 
detection or diagnosis due to substantial numbers of false positive and false 
negative readings.11 High levels are also observed in other gastrointestinal 
malignancies including biliary, hepatocellular, colorectal and gastric cancer. 
A systemic review found an overall sensitivity of 81% and specificity of 90% 
for pancreatic carcinoma.11 A value higher than 1000 U/mL usually indicates 
digestive cancer, with nearly 100% specificity for pancreatic carcinoma.12 
Investigators from India demonstrated that a level above 300 U/ml in mass 
lesions in chronic pancreatitis was always indicative of malignancy.13 However, 
apart from chronic pancreatitis, Ca 19 - 9 can also be elevated in other benign GI 
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diseases like cirrhosis, primary sclerosing cholangitis, bacterial cholangitis or 
choledocholithiasis, actually any condition associated with cholestasis.14-16
In our national AIP cohort, elevated levels of Ca 19 - 9 were encountered in the 
majority of patients. Levels above 34 U/ml were found in 58%, above 100 U/ml 
in 38% and above 300 U/ml in 18% of cases. Several patients even had levels 
as high as 5000 to 23.000 U/ml.17 Elevated levels in AIP were also reported in 
other cohorts.18-23
In this study, we aimed to evaluate Ca 19 - 9 levels in AIP, pancreatobiliary 
malignancies and benign diseases that show clinical similarity with AIP. 
Secondly we aimed to assess the performance of Ca 19 - 9 as a diagnostic 
test to differentiate between AIP and pancreatic carcinoma, single and in 
combination with IgG4.
PATIENTS AND METHODS
PATIENTS
Between March 2007 and May 2011 sera were prospectively obtained from 
consecutive patients presenting with AIP (n=33), pancreatic carcinoma (n=53), 
cholangiocarcinoma (n=32), chronic pancreatitis (n=52), primary sclerosing 
cholangitis (n=30) and Sjögren’s syndrome (n=31). Sera were obtained with 
informed consent and were processed immediately, or stored at -80°C. 
The diagnosis of AIP was made according to the International Consensus 
Diagnostic Criteria, Asian or HISORT criteria, or a combination of unexplained 
pancreatic disease, biliary disease/extrapancreatic manifestations and either 
response to steroids or IgG4-positive serology.17, 24-26 Sera of chronic pancreatitis 
patients were collected from patients with chronic alcoholic, obstructive or 
idiopathic pancreatitis. Diagnostic criteria systems of AIP were systematically 
applied to all patients with chronic pancreatitis to exclude misclassification. 
Sera of pancreatic carcinoma or cholangiocarcinoma patients were included 
only if diagnosis was histologically confirmed. PSC and Sjögren’s syndrome 
patients were diagnosed according to accepted criteria.27-28
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LABORATORY MEASUREMENTS
Serum Ca 19 - 9 levels were measured using an electrochemiluminescense 
immunoassay (ECLIA) on a Modular Analytics E module (Roche Diagnostics Co, 
Tokyo, Japan). The upper limit provided by the manufacturer was 34 U/ml. 
IgG4 levels were determined on the Immage 800 Analyzer (Beckman Coulter, 
Mijdrecht, the Netherlands) using the Peliclass IgG subclass nephelometry 
kit according to manufacturer’s instructions (Sanquin, Amsterdam, the 
Netherlands). The upper limit of normal provided by the manufacturer was 
1.40 g/l.
STATISTICAL ANALYSIS
Ca 19 - 9, IgG4 and bilirubin levels were expressed as median value with 
interquartile range (IQR). One-way analysis and pairwise comparisons with 
Bonferroni correction for multiple testing were performed to detect significant 
differences between groups. P values < 0.05 were considered statistically 
significant. Mann Whitney U test was performed to detect differences in 
laboratory parameters in subgroups of AIP patients (with or without mass 
presentation, steroid use and proximal biliary involvement). Logistic regression 
analysis was applied to study the simultaneous effect of Ca 19 - 9, IgG4 
and bilirubin. ROC analysis was performed to assess optimal cut-off levels. 
Test characteristics of Ca 19 - 9, IgG4 and combination were calculated. 
Statistical analysis was carried out using SPSS Statistics 20.0 Software (IBM, 
New York, USA).
MEDICAL ETHICAL CONCERNS
The study was approved by the institutional review board of the Erasmus 
University Medical Center, Rotterdam, the Netherlands.
RESULTS
CA 19 - 9 AS PREDICTOR OF AIP
Patient characteristics and laboratory measurements are shown in Table 1. 
The distribution of Ca 19 - 9 for the different groups is shown in Figure 1. Ca 19 - 9 
was significantly higher in pancreatic carcinoma (median 349 U/ml, IQR 63 - 1588) 
60
T
a
b
le
 1
 P
at
ie
n
t 
ch
ar
ac
te
ri
st
ic
s
A
IP
P
a
n
cr
e
a
ti
c
ca
rc
in
o
m
a
C
h
o
la
n
g
io
-
ca
rc
in
o
m
a
C
h
ro
n
ic
p
a
n
cr
e
a
ti
ti
s
P
S
C
S
jö
g
re
n
’s
 
sy
n
d
ro
m
e
p
-o
v
e
ra
ll
N
u
m
b
er
3
3
5
3
3
2
5
2
3
0
3
1
A
g
e 
(y
r)
6
5
 (
5
5
 - 7
3
)
6
6
 (
6
0
 - 7
1
)
6
6
 (
5
7
 - 7
3
)
5
2
 (
4
4
 - 6
0
)
4
6
 (
4
0
 - 5
3
)
n
.a
.
<
 0
.0
0
1
1
M
al
e 
(n
,%
)
2
8
 (
8
5
%
)
2
7
 (
5
1
%
)
1
5
 (
4
7
%
)
3
6
 (
6
9
%
)
2
3
 (
7
7
%
)
3
 (
1
0
%
)
<
 0
.0
0
1
2
C
a 
1
9
 - 9
(U
/m
l)
2
6
(1
2
 - 1
0
8
)
3
4
9
(6
3
 - 1
5
8
8
)*
2
4
7
(4
1
 - 2
1
7
5
)*
1
0
(6
 - 2
4
)
5
9
(2
3
 - 1
5
4
)
6
(4
 - 1
5
)*
<
 0
.0
0
1
1
Ig
G
4
(g
/L
)
4
.7
(1
.8
 - 1
0
.5
)
0
.5
(0
.2
 - 1
.1
)*
0
.6
(0
.3
 - 1
.7
)*
0
.6
(0
.3
 - 1
.1
)*
0
.5
(0
.2
 - 0
.9
)*
0
.2
(0
.1
 - 0
.5
)*
<
 0
.0
0
1
1
Bi
lir
u
b
in
 
(μ
m
o
l/
L)
1
0
(8
 - 3
4
)
1
5
(9
 - 5
7
)
2
3
(8
 - 5
7
)
7
(5
 - 1
1
)
3
8
(1
5
 - 1
0
9
)
0
(0
 - 1
)
<
 0
.0
0
1
1
A
g
e 
a
n
d
 l
a
b
or
a
to
ry
 t
es
ts
 i
n
 m
ed
ia
n
 (
in
te
rq
u
a
rt
ile
 r
a
n
g
e)
. 
A
IP
: 
a
u
to
im
m
u
n
e 
p
a
n
cr
ea
ti
ti
s,
 P
SC
: 
p
ri
m
a
ry
 s
cl
er
os
in
g
 c
h
ol
a
n
g
it
is
, 
n
.a
: 
n
ot
 
a
va
ila
b
le
. 
1
on
e 
w
a
y 
a
n
a
ly
si
s 
of
 v
a
ri
a
n
ce
 t
o 
d
et
ec
t 
d
iff
er
en
ce
s 
b
et
w
ee
n
 g
ro
u
p
s,
 w
it
h
 *
 p
<
 0
.0
5
 b
et
w
ee
n
 A
IP
 a
n
d
 g
ro
u
p
 (
p
os
t 
h
oc
 p
a
ir
ed
 t
es
t 
w
it
h
 
co
rr
ec
ti
on
 f
or
 m
u
lt
ip
le
 t
es
ti
n
g
).
 2
Fi
sh
er
’s
 e
xa
ct
 t
es
t.
61
and cholangiocarcinoma (median 247 U/ml, IQR 41 - 2175) than in AIP (median 
26 U/ml, IQR 12 - 108), p < 0.001. The level in AIP was significantly higher than in 
Sjögren’s syndrome (median 6 U/ml, IQR 4 - 15), p=0.009. In AIP, Ca 19 - 9 levels 
showed a wide distribution with minimum of 1 U/ml and maximum of 23283 
U/ml. Moreover, in PSC markedly elevated levels were also observed (median 
59 U/ml, IQR 23 - 154), minimum 6, maximum 885 U/ml. The median Ca19 - 9 
level in PSC patients however was significantly lower than in patients suffering 
from cholangiocarcinoma (p=0.009). The unadjusted effect of Ca 19 - 9 as a 
predictor of AIP against pancreatic carcinoma showed a strong association of low 
Ca 19 - 9 with high probability of AIP (OR=0.42; 95%CI (0.25 - 0.70), p=0.0002, 
Supplementary Table). Serum IgG4 was significantly higher in patients with AIP 
than in all other groups (p< 0.001, Table 1). In particular, IgG4 was significantly 
higher in the AIP group compared to patients with pancreatic carcinoma. Levels 
of bilirubine did not differ between AIP and malignancy. After adjustment for 
IgG4 and bilirubin, Ca 19 - 9 remained an independent predictor of AIP against 
pancreatic carcinoma (OR=0.28; 95%CI(0.13 - 0.59), p=0.0001). IgG4 was strongly 
associated with AIP, while bilirubin was not significantly associated with AIP (all 
p-values > 0.17, results not shown).
Figure 1 Ca 19 - 9 level in pancreatobiliary diseases and Sjögren’s syndrome
Levels of Ca 19 - 9 are expressed in U/ml, as grey boxes (interquartile range) with median 
(horizontal line within box) and whiskers (range that contains 95% of observations).. AIP: 
autoimmune pancreatitis, PAC: pancreatic adenocarcinoma, CC: cholangiocarcinoma, CP: 
chronic pancreatitis, PSC: primary sclerosing cholangitis, SS: Sjögren’s syndrome. *p< 0.05 
between AIP and group.
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CA 19 - 9 IN SUBGROUPS OF AIP PATIENTS
In addition to the analysis above, the distribution of Ca 19 - 9 within specific 
subgroups of AIP patients were studied. In AIP patients, Ca 19 - 9 levels were 
not significantly different between patients with or without mass presentation 
(p=0.24), steroid use (p=0.88) or proximal biliary involvement (p=0.17) 
(Table 2). IgG4 and bilirubin levels differed significantly in subgroups with or 
without steroids (p=0.047 and p=0.002). Furthermore, a sensitivity analysis of 
Ca 19 - 9 as predictor for AIP was performed in these subgroups. Results of the 
unadjusted effects (Ca 19 - 9 only) as well as the adjusted effects (adjusted for 
IgG4 and bilirubin) in the different subgroups supported the overall findings.
DIAGNOSTIC CHARACTERISTICS OF CA 19 - 9 AND IGG4
The optimal cut-off point for distinction between pancreatic carcinoma and AIP 
was assessed by ROC analysis, as shown in Figure 2. The area under the curve 
for Ca 19 - 9 as predictor for the presence of pancreatic carcinoma was 0.77 
(0.66 - 0.87). The optimal cut-off level was 74 U/ml, yielding a sensitivity of 76% 
and specificity of 75%, with LR+ of 2.94 and LR- of 0.35. The optimal cut-off 
for IgG4 was 2.6 g/L, yielding a sensitivity of 70% and specificity of 100%, with 
LR+ ∞ (infinite) and LR- 0.3.
Table 2 Subgroups of AIP patients: characteristics and relation to Ca 19 - 9, bilirubin and IgG4
Subgroups Present Absent p-level1
Mass Number, n (%) 12 (38%) 20 (63%)
Ca 19 - 9 (U/ml), median (IQR) 16 (8 - 56) 34 (12 - 225) 0.236
Bilirubin (μmol/l), median (IQR) 9 (7 - 19) 12 (8 - 55) 0.224
IgG4 (g/l), median (IQR) 2.9 (1.4 - 7.5) 5.0 (2.3 - 11.7) 0.373
Steroid therapy Number, n (%) 9 (28 %) 23 (72%)
Ca 19 - 9 (U/ml), median (IQR) 37 (13 - 67) 26 (12 - 234) 0.881
Bilirubin (μmol/l), median (IQR) 9 (7 - 11) 14 (8 - 61) 0.047*
IgG4 (g/l), median (IQR) 1.8 (0.7 - 4.0) 5.4 (3.4 - 13.6) 0.002*
Proximal biliary 
involvement2
Number, n (%) 13 (50%) 13 (50%)
Ca 19 - 9 (U/ml), median (IQR) 74 (13 - 251) 25 (6 - 58) 0.168
Bilirubin (μmol/l), median (IQR) 20 (10 - 62) 10 (9 - 20) 0.264
IgG4 (g/l), median (IQR) 5.08 (2.6 - 15.9) 1.89 (1.3 - 4.9) 0.060
* p < 0.05; 1 Mann-Whitney U Test; 2 Biliary involvement other than intrapancreatic part of 
common bile duct
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The diagnostic performance of Ca 19 - 9 and IgG4, single and in combination, 
are shown in Table 3 and Figure 3. Ca 19 - 9 as a single marker had moderate 
sensitivity (73%), and specificity (74%). IgG4 levels higher than 1.4 g/L were 
Figure 2 Receiver operating curve for Ca 19 - 9
The area under the curve (AUC) for the diagnosis of pancreatic carcinoma by means of Ca 
19 - 9 levels was 0.77
Table 3 Diagnostic performance of Ca 19 - 9 and IgG4, single and combined, to differentiate 
AIP from pancreatic carcinoma
Ca 19 - 9 
≤ 74
IgG4  
> 1.4
IgG4  
> 2.6
Ca 19 - 9 ≤ 74 & 
1.0 < IgG4 ≤ 2.6
or IgG4 > 2.6
Ca 19 - 9 ≤ 74 & 
1.4 < IgG4 ≤ 2.6
or IgG4 > 2.6
True positive (n) 24.0 28.0 23.0 29.0 26.0
Sensitivity (%) 72.7 84.8 69.7 93.5 83.9
Specificity (%) 73.6 81.1 100.0 100.0 100.0
PPV (%) 63.2 73.7 100.0 100.0 100.0
NPV (%) 81.2 89.6 84.1 96.4 91.4
LR + 2.8 4.5 ∞ ∞ ∞
LR - 0.4 0.2 0.3 0.1 0.2
AUC 
(95% c.i.)
0.77
(0.66 - 0.87)
0.91
(0.83 - 0.99)
0.91
(0.83 - 0.99)
0.97
(0.92 - 1.00)
0.92
(0.84 - 1.00)
PPV = positive predictive value, NPV = negative predictive value, LR = likelihood ratio of + 
positive or - negative test, AUC = area under the receiver operating curve, c.i. = confidence 
interval. Value of Ca 19 - 9 in U/ml, IgG4 in g/L.
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more sensitive (85%) but moderately specific (81%). Raising the cut-off to 
2.6 g/L improved specificity to 100%, at the cost of lowering sensitivity to 
70%. However, if low levels of Ca 19 - 9 (< 74 U/ml) were combined with IgG4, 
specificity rose to 100% and sensitivity improved to 84% if IgG4 > 1.4 and 94% if 
IgG4 > 1.0 g/L.
DISCUSSION
In this study we found that low levels of Ca 19 - 9 were an independent 
predictor of AIP after adjustment for IgG4, thus Ca 19 - 9 appears to provide 
additional information to distinct between AIP and pancreatic carcinoma. As a 
single test, both Ca 19 - 9 and IgG4 were not optimal for identification of AIP. 
The most accurate identification of AIP patients from pancreatic carcinoma was 
achieved with the combination of low levels of Ca 19 - 9 (< 74 U/ml) and high 
Sens 84% 
Spec100% 
Sens 94 % 
Spec 100% 
Figure 3 Combination of Ca 19 - 9 and IgG4 to differentiate AIP from pancreatic 
carcinoma
Circles represent patients with pancreatic carcinoma, dots represent AIP patients. If low 
levels of Ca 19 - 9 (< 74 U/ml) were combined with IgG4, specificity rose to 100% with a 
sensitivity of 84% if 1.4 <IgG4 ≤ 2.6 or IgG4 > 2.6 (grey area) and a sensitivity of 94% if 
1.0 <IgG4 ≤ 2.6 or IgG4 > 2.6 (diagonally striped area).
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levels of IgG4 (> 1.0 g/L), which shows sensitivity of 94% and specificity of 
100%. Our findings hold true for subgroups of AIP patients.
In contrast to previous reports, high levels of Ca 19 - 9 were not diagnostically 
helpful. The marked overlap of values in AIP and cancer limit the value of 
Ca 19 - 9 in clinical decision making. We observed very high Ca 19 - 9 levels 
ranging from 5000 - 23000 U/ml in several AIP patients, as was reported 
previously.29 Previous studies found elevated Ca 19 - 9 levels in about 25% of 
AIP cases18, 20, 22 as compared to 58% in the present series. In another study 
addressing the role of Ca 19 - 9 in differentiating pancreatic carcinoma from 
AIP, investigators found a sensitivity of 62% and specificity of 92% for values 
higher than 150 U/ml. The authors concluded that Ca 19 - 9 levels higher 
than 150 U/ml are highly specific for pancreatic carcinoma and thus may be 
useful in differential diagnosis. The different result of the present study may 
be attributable to differences in patient selection as illustrated by the higher 
frequency and also higher values of elevated Ca 19 - 9 in our cohort. This might 
be explained by differences in proximal biliary involvement, which was more 
frequent in our AIP patients (50% versus 31 - 34%17-18). However, median levels 
of bilirubin were not different in patients with or without proximal biliary 
involvement and bilirubin was not a confounding variable.
In general, the interpretation of elevated Ca 19 - 9 levels is difficult for several 
reasons. First, Ca 19 - 9 is a sialylated Lewis antigen. Seven to 10% of Caucasians 
(increasing to 22% in Africans) are Lewis negative and are unable to synthesize 
Ca 19 - 9.30 Second, Ca 19 - 9 can also be elevated in benign pancreatic diseases, 
which often coexist with pancreatic carcinoma. Third, Ca 19 - 9 undergoes some 
degree of biliary excretion and is produced by biliary epithelial cells. Therefore 
in cholestasis, levels are frequently elevated even in benign conditions.31-32 
Treatment of these conditions may result in normalization.14-16 In our study, low 
Ca 19 - 9 was a strong predictor of AIP, even after adjustment for bilirubin.
For the clinically highly relevant question how to differentiate pancreatic 
carcinoma from AIP, a test with very high sensitivity and specificity is needed. 
In this patient group however, the importance of a high sensitivity outweighs 
a high specificity. A positive test may prompt the decision to perform surgery. 
In this case clinicians are more willing to accept false positivity (lower 
specificity) than false negativity (lower sensitivity). The former will lead to a 
resection with postoperative benign histology (which is generally observed 
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in 5 - 11% of pancreatoduodenectomies1, 33-38), the latter means that patients 
are deprived of the only chance for cure in the case of true carcinoma. 
As single tests, Ca 19 - 9 (< 74 U/ml) and IgG4 (> 2.6 g/L) would entail 27% 
and 30% false negative cases respectively. In other words, one quarter to one 
third of patients with cancer would be erroneously treated with prednisone 
and potentially deprived of a curative surgical resection. Furthermore, this 
corresponds with 26% false positive cases in case of Ca 19 - 9, one quarter of 
patients undergoing resection would be erroneously exposed to a surgical 
procedure with substantial morbidity (46%)35 and mortality (though in large 
volume centers less than 5%39). IgG4 levels of > 2.6 g/L are 100% specific, thus 
raising the normal cut-off (1.4 g/L) to this level would protect AIP patients from 
unnecessary surgery. For comparison, in large cohorts of AIP patients, 16 - 30% 
underwent resection.17, 20, 22, 24, 40 This optimal cut-off level of IgG4 is in line with 
previous observations, which suggested a level of 2.8 g/L (twice the upper limit 
of normal).4, 6 In our study, IgG4 levels higher than 1.4 g/L were fairly sensitive 
for AIP (85%) but not very specific (81%). Interestingly, if low levels of Ca 19 - 9 
(< 74 U/ml) were combined with IgG4, specificity rose to 100% and sensitivity 
improved to 84% if IgG4 > 1.4 and 94% if IgG4 > 1.0. Thus, low levels of Ca 19 - 9 
improve both the moderate specificity of intermediate IgG4 levels, as the poor 
sensitivity of high IgG4 levels.
To determine the quality of a diagnostic test in clinical practice, most studies 
report predictive values. In diseases with low prevalence however, this 
might cause overestimation of the quality of the test. The likelihood ratio of 
positive (LR+) and negative result (LR-), are the stable characteristics of a test, 
independent of prevalence.41 In our study, LR+ of IgG4 > 2.6, or intermediate 
levels of IgG4 in combination with Ca 19 - 9 < 74 U/ml, were infinite. That means 
that these levels definitely rule in diagnosis of AIP. Values of these markers 
outside this range have less capacity to rule out AIP as reflected by their LR-.
Although the use of Ca 19 - 9 is advocated in several diagnostic algorithms for 
AIP, as far as we aware, this is the first study addressing the combination of 
both markers to improve the diagnostic power in discrimination between AIP 
and pancreatic cancer. The strengths of our study include the diversity of the 
control groups and the careful selection of patients. Malignancy was always 
confirmed with histology, and chronic pancreatitis patients were excluded 
if they scored positive on diagnostic criteria systems for AIP. Furthermore, 
we believe that expressing the value of this test in terms of likelihood ratios 
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gives a more accurate reflection of its use in daily practice than the commonly 
reported sensitivity, specificity and predictive values.
Two possible sources of misclassification bias are present in this study. 
For diagnosing AIP we used generally accepted diagnostic criteria systems 
as gold standard. This might, but does not always, include histological 
proof. In theory, some of these patients could have been wrongly classified 
as AIP while having malignancy. However, all patients in our cohort were 
observed at least two years, which virtually rules out cancer. In patients 
with cholangiocarcinoma, several patients with underlying PSC were 
included. We cannot rule out the possibility of occult malignancy in PSC 
patients. Our study was not designed to address this particular issue. 
This renders any conclusion regarding the Ca19 - 9 values in PSC in relation to 
cholangiocarcinoma less reliable.
In conclusion, the present study showed that low levels of Ca 19 - 9 
independently predict AIP against pancreatic carcinoma. Both Ca 19 - 9 and 
IgG4 are not optimal as single markers. The most accurate identification of AIP 
patients was achieved with the combination of Ca 19 - 9 (< 74 U/ml) and IgG4 
(> 1.0 g/L), which showed sensitivity of 94% and specificity of 100%.
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SUPPLEMENTARY MATERIAL
Supplementary Table Logistic regression analysis assessing the effect of Ca 19 - 9, in 
the total cohort of AIP patients and 3 different subgroups, as predictor for AIP, unadjusted 
and adjusted for IgG4 and bilirubin
Unadjusted effect Adjusted for IgG4 and bilirubin
OR (95% CI) p-value OR (95% CI) p-value
Total AIP 0.42 (0.25 - 0.70) 0.0002 0.28 (0.13 - 0.59) 0.0001
AIP with mass 0.32 (0.15 - 0.67) 0.0006 0.07 (0.01 - 0.51) < 0.0001
AIP steroid naïve 0.50 (0.29 - 0.85) 0.0066 0.21 (0.07 - 0.62) 0.0006
AIP proximal biliary 
involvement excluded
0.41 (0.22 - 0.78) 0.0030 0.27 (0.11 - 0.68) 0.0010
Sensitivity analysis (logistic regression analysis) was performed for the total cohort of AIP 
patients, patients presenting with a mass lesion, those who were steroid naïve and those 
without proximal biliary involvement. OR=odds ratio, CI= confidence interval.
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ABSTRACT
Autoimmune pancreatitis (AIP) is associated with a marked elevation of serum 
total IgG4. Although there is evidence of autoimmunity in AIP, there are also 
signs of an allergic nature of its pathogenesis. Therefore we determined both 
IgE and IgG4 in 13 patients with AIP, in 12 patients with pancreatic carcinoma, 
and in 14 patients with atopic allergy, and investigated the relationship 
between IgE and IgG4. Total IgG4 was determined by automated nephelometry 
and total IgE by automated enzyme fluoroimmunoassay. Both total IgE and 
total IgG4 of AIP patients were significantly higher than these levels in patients 
with pancreatic carcinoma (p= 0.0004 and p = 0.015 respectively). There was 
a significant correlation between the total IgE and total IgG4 levels in patients 
with AIP and patients with atopic allergy (rs = 0.82 , p=0.0006 and rs = 0.88 , 
p< 0.0001, respectively). The IgE/ IgG4 ratio in sera from patients with atopic 
allergy was significantly different (p=0.0012) from this ratio in sera from 
patients with AIP. These results suggest that analysis of total IgE in serum might 
be useful in the differentiation between autoimmune pancreatitis and pancreatic 
carcinoma.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is the pancreatic manifestation of a systemic 
inflammatory disorder, characterized by infiltration of IgG4 positive plasma 
cells and marked interstitial fibrosis, which is responsive to steroid therapy.1,2 
Extrapancreatic manifestations of the disease include cholangitis, retroperitoneal 
fibrosis, Mikulicz’s disease, interstitial nephritis and pseudotumours of lungs 
en mediastinum.1,3 If located to the pancreatobiliary region, the disorder may 
mimic cancer of the pancreatic head or cholangiocarcinoma. In approximately 5 
% of pancreatoduodenectomies performed for suspicion of pancreatic carcinoma 
the resected lesion turns out to be a benign, inflammatory lesion.4 Hamano et 
al.,5 who were the first to report high serum IgG4 concentrations in 20 Japanese 
patients with autoimmune pancreatitis, found that a serum IgG4 level of > 1.35 
g/L had 95% sensitivity and 97% specificity for the differentiation of AIP from 
pancreatic cancer. They suggested that the measurement of serum IgG4 in 
patients suspected of having pancreatic cancer may help reduce the incidence 
of unnecessary surgery. In a western population of 45 patients, Ghazale et al.6 
noted a 76% sensitivity and 93% specificity of a serum IgG4 level of > 1.40 g/L. 
This difference in sensitivity between Japanese and western populations may 
be caused by the occurrence of two subsets in AIP: type 1 AIP and type 2 AIP,7 
of which only type 1 is characterized by elevated serum IgG4 and an increased 
IgG4-positive lymphoplasmacytic infiltrate. The pathogenesis of AIP is unclear. 
The inflammatory reaction has both characteristics of autoimmune (Th1- mediated) 
and allergic (Th2- mediated) responses.8,9 Okazaki et al.8 proposed a biphasic 
mechanism consisting of “induction” by pro-inflammatory cytokines produced 
by Th1 cells and “progression” by Th2 immune responses. When an allergy-like 
reaction is part of the progression of the disease, IgE levels might be elevated 
in AIP. Hamano et al.5 found no significant difference in total IgE level between 
20 patients with sclerosing pancreatitis and 20 normal individuals. Umemura et 
al.10 found an elevated serum total IgE in 35% of 17 patients with autoimmune 
pancreatitis. After 4 weeks of glucocortocoid therapy of 7 patients, both IgG4 and 
IgE decreased to a level of about 30% of the median pretreatment value.10 Masaki et 
al.11 reported a 20-fold higher total IgE level in 64 patients with IgG4-positive multi-
organ lymphoproliferative syndrome compared with 33 patients with Sjögren’s 
syndrome (Ss), the total IgG4 level of these 64 patients was about 30-fold higher 
than this level in the 33 Ss patients. In the present study we further investigated 
the relationship between serum total IgE and total IgG4 in patients with AIP, 
in patients with pancreatic carcinoma and in patients with atopic disease.
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PATIENTS AND METHODS
Sera from patients with AIP and from patients with pancreatic carcinoma were 
collected simultaneously with samples drawn for routine clinical chemistry 
analysis, after informed consent was obtained. Of the patients diagnosed 
with AIP, using the HISORt diagnostic criteria proposed by the Mayo Clinic,6 
11 patients had autoimmune pancreatocholangitis, 1 patient had autoimmune 
pancreatitis and 1 patient (with a total serum IgG4 of 87 g/L) had a provisional 
diagnosis of cholangitis and IgG4 associated autoimmune hepatitis, which has 
been recognised by Umemura et al as the hepatic manifestation of IgG4 related 
disease.10 The medical history of these 13 patients did not mention inhalant 
or food allergies. Sera with total IgE levels evenly distributed over the range 
0 - 7500 kU/L were selected from left-over samples, previously submitted for 
routine IgE antibody measurements. Sera from patients with cystic fibrosis, 
some of which have an elevated total IgE caused by allergic bronchopulmonary 
aspergillosis,12 were excluded, because of frequent pancreatic pathology in 
these patients.13 The median age of the patients with AIP, pancreatic carcinoma, 
or atopic allergy was 69, 66, and 37 years, and the male/female ratio 12/1, 
5/7 and 9/5 respectively. Sera were stored at -20° C. Total IgE was determined 
on the ImmunoCAP 250 system, according to the manufacturer’s instructions 
(Phadia, Nieuwegein, Netherlands). IgG subclasses were determined on the 
Immage 800 analyzer (Beckman Coulter, Mijdrecht, Netherlands) using the 
Peliclass IgG subclass nephelometry kit according to the manufacturer’s 
instructions (Sanquin, Amsterdam, Netherlands). This manufacturer gives a 
value of 1.4 g/L as upper reference limit for serum total IgG4 in adults.
The study was approved by the Institutional Review Board of the Erasmus 
University Medical Center.
For statistical analysis of the data we used Graph Pad Prism for Windows, 
version 5.01, Graph Pad Software, San Diego, CA, USA. For comparison between 
groups the Mann-Whitney test was applied. The relation between total IgG4 
and total IgE within groups was analysed by the Spearman rank correlation 
test. For analysis of the difference between ROC curves, derived from the same 
samples, we used Medcalc Version 11.3, Medcalc Software, B-9030 Mariakerke, 
Belgium.
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RESULTS
Both total IgE and total IgG4 of the 13 AIP patients were significantly higher than 
these levels in 12 patients with pancreatic carcinoma (p= 0.0004 and p = 0.015 
respectively) (Fig 1 and 2). No significant difference was observed for total IgE 
and total IgG4 between the 13 AIP patients and 14 atopic patients (p=0.14 and 
p= 0.07 respectively). Total IgE in the atopic group was significantly higher than 
this level in the patients with pancreatic carcinoma (p < 0.0001). This was not 
the case for total IgG4 (p=0.21) (Fig 1 and 2). The diagnostic power of serum IgE 
and IgG4 for discrimination between AIP and pancreatic carcinoma was analyzed 
by calculation of receiver operating characteristic (ROC) curves (fig 3) for the 
combined data from the AIP patients and the patients with pancreatic carcinoma. 
At a level of 1.6 g/L, total IgG4 had 69% sensitivity and 92% specificity. At a level 
of 138 kU/L, total IgE had 77% sensitivity and 100% specificity. Although the area 
under the curve (AUC) for IgE (0.923) was larger than the AUC for IgG4 (0.788), 
this difference did not reach statistical significance (p=0.15), probably because of 
the small number of patients involved.
There was a significant correlation between total IgE and total IgG4 levels in 
the AIP patients, as well as in the patients with IgE-mediated allergy (rs = 0.82, 
p=0.0006, respectively rs = 0.88, p< 0.0001) (Figure 4). In the samples from 
Figure 1 Serum total IgE in AIP, pancreas 
carcinoma and atopics
Horizontal bars: median IgE level: 244, 24, 
and 833 kU/l.
Figure 2 Serum total IgG4 in AIP, pancreas 
carcinoma and atopics
Horizontal bars: median IgG4 level: 3.70, 
0.62, and 1.08 g/l. Three sera with a total 
IgG4 level of < 0.05 g/L were assigned a 
value of 0.05 g/L.
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patients with pancreatic carcinoma low levels of both IgE and IgG4 were 
found, without a significant correlation between these two variables (rs = 0.14, 
p=0.65). The IgE and IgG4 levels in Figure 4 suggest that the AIP patients and 
the atopic patients have a different etiology. However, the pancreas-carcinoma 
patients show a trend similar to the AIP group. Indeed, when we compared 
the IgE/ IgG4 ratio’s of the individual samples of the three different groups, 
we found a significant difference between AIP patients and atopic patients. 
In Figure 5 the IgE/ IgG4 ratio is depicted for the same sera shown in Figure 4. 
The IgE/ IgG4 ratio for sera from patients with atopy was significantly different 
(p=0.0012) from this ratio in sera from patients with AIP and also significantly 
different from patients with pancreatic carcinoma (p< 0.0001). Interestingly, 
Figure 3 ROC curves for the combined data from AIP patients and patients with 
pancreatic carcinoma
Figure 4 Relationship between total IgG4 and total IgE in AIP, pancreatic carcinoma and atopics
AIP : rs = 0.82, p=0.0006 and atopics : rs = 0.88, p< 0.0001. Three sera with a total IgG4 
level of < 0.05 g/L were assigned a value of 0.05 g/L.
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the IgE/ IgG4 ratio in sera from patients with pancreatic carcinoma was not 
significantly different from this ratio in sera from AIP patients (p=0.09).
The serum with a total IgG4 level of 87 g/L was tested for the presence of a 
monoclonal immunoglobulin by serum electrophoresis/immunofixation with 
the Sebia Hydrasys system (Sebia, Vilvoorde, Belgium). However, a polyclonally 
elevated IgG was observed.
DISCUSSION
IgG4 is the least abundant of the four human IgG subclasses. Aalberse et 
al14,15 have shown that prolonged allergen-exposure leads to the formation of 
specific IgG4 antibodies, whose main function was thought to suppress IgE-
mediated inflammation. Likewise, Okazaki et al.8 indicated that in autoimmune 
pancreatitis, IgG4 or IgG4-immunecomplexes are unlikely to be pathogenic 
factors, but may also act as anti-inflammatory factors. In autoimmune 
pancreatitis and associated pathology, total IgG4 can exceed the concentrations 
of the other subclasses. Kawa et al.16 described total IgG4 levels up to 40 
g/L. One of the patients in this study had a total IgG4 level of 87 g/l, a level 
that would suggest the presence of a monoclonal gamma-globulin. However, 
immunofixation/electrophoresis showed that serum from this patient contained 
highly elevated polyclonal IgG.
Figure 5 Serum IgE/IgG4 ratio in AIP, pancreatic carcinoma and atopics
Horizontal bars: median IgE/IgG4 ratio 87, 49, and 1234 kU/g. Three sera with a total 
IgG4 level of < 0.05 g/L were assigned a value of 0.05 g/L.
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The median total IgE level of the patients with pancreatic cancer (24 kU/L) is 
close to a recently published value (21.7 kU/L) for non-atopic individuals.17 
The IgE/ IgG4 ratio in atopic patients was significantly higher than this ratio in 
AIP patients and in patients with pancreatic carcinoma (Figure 4). The difference 
in median age between the atopic patients (37 years) and the AIP patients (69 
years) does not explain the difference in IgE/ IgG4 ratios: the median total 
IgE level of the US population (including atopic individuals) was 38.0 kU/l for 
30 - 39 year-old persons and 36.6 kU/l for 60 - 69 year-old individuals in 2005.17
In the study of Hamano et al.5 total IgE was not significantly different between 
AIP patients and normal individuals, whereas in the present study IgE was 
significantly higher in AIP patients that in patients with pancreatic carcinoma. 
The Elisa used by Hamano et al. for total IgE analysis was not specified. 
We used the automated ImmunoCAP system with calibrators traceable to the 
WHO preparation 75/502 for human IgE. Our results are in line with the data 
published by Masaki et al.,11 who reported a 20-fold higher total IgE level in 
64 patients with IgG4-positive multi-organ lymphoproliferative syndrome 
compared with 33 patients with Sjögren’s syndrome. The correlation we 
observed between serum total IgE and IgG4 (Figure 4) could theoretically be 
explained by a novel heterophilic antibody activity of IgG4, proposed by Ito 
et al..18 The significant difference between the IgE/IgG4 ratio’s of AIP patients 
and atopic patients (Figure 5) however makes this explanation unlikely. 
Furthermore, we found no evidence for heterophilic antibody interference in 
the total IgE assay, that was used in the present study, even in sera that showed 
high interference in the Unicap tryptase immunoassay (Supplementary Table).
To our knowledge this is the first report that describes a correlation between 
serum total IgG4 and total IgE in atopic individuals and in patients with 
autoimmune pancreatitis. Meiler et al.19 showed that T regulatory cells regulate 
antibody isotypes, which may contribute to the suppression of inflammatory 
diseases by the induction of specific IgG4 and by the suppression of specific 
IgE. It is remarkable therefore to find a close association between total IgG4 
and total IgE both in atopic individuals and in patients with autoimmune 
pancreatitis. Zen et al.9 concluded that the predominant Th2 and regulatory 
immune reactions in AIP might reflect an allergic nature in their pathogenesis. 
The simultaneous elevation of both IgG4 and IgE in AIP and the correlation 
between these two markers supports this view. Choi et al.20 recently 
suggested that in AIP there may be a defect in the function of regulatory 
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T cells, which normally prevents autoimmune disease progression via a 
suppressor mechanism. Regulatory T cells also play a role in the suppression of 
IgE-mediated allergy.19,21 An abnormality in regulatory T cells therefore could be 
the common cause of elevated IgE and IgG4 in AIP.
In summary, our results suggest that analysis of total IgE in serum might be 
useful in the differentiation between autoimmune pancreatitis and pancreatic 
carcinoma. A limitation of our study is the small number of patients involved. 
A more accurate estimation of the diagnostic value of total IgE would require a 
larger number of patients. Metz22 indicated that about 100 samples are needed 
for meaningful conclusions to be drawn from ROC analysis.
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SUPPLEMENTARY MATERIAL
Supplementary Table Serum tryptase, human anti-mouse antibodies (Hama) and total 
IgE in sera before and after incubation of these sera in Heterophilic blocking tubes (HBT).
Tryptase Tryptase Hama Hama Total IgE Total IgE
ug/l ug/l ng/ml ng/ml kU/l kU/l
without HBT with
HBT
without
HBT
with
HBT
without HBT with
HBT
6.91 6.59 < 1.5 < 1.5 413 372
7.96 5.37 21.1 < 1.5 5.34 4.93
4.77 4.45 < 1.5 < 1.5 5.92 4.73
5.92 4.02 3.4 < 1.5 53 50.2
52.1 5.78 25.9 1.6 83.7 97.4
3.34 3.37 < 1.5 < 1.5 13.5 13.2
6.65 6.4 < 1.5 < 1.5 230 219
4.38 4.4 1,6 < 1.5 31 27.2
21.3 14.4 40.8 < 1.5 1109 1140
10.1 4.36 43.2 < 1.5 20.6 16.4
7.08 5.18 5.6 < 1.5 19.2 21
13.8 4.36 92.1 < 1.5 49.2 47.1
5.11 3.33 46.7 < 1.5 41.2 37.4
84.6 7.47 254 < 1.5 3.95 3.86
11.8 9.03 21.7 < 1.5 368 323
Estimation of serum tryptase and Hama and incubation of sera in HBT were performed 
as described in: van Toorenenbergen AW, Hooijkaas H, Klein Heerenbrink G, Dufour-
van den Goorbergh DM. Heterophilic antibody interference in a tryptase immunoassay. 
Clin Biochem 2008;41:331 - 334. In four sera HBT treatment caused > 50% reduction 
of serum tryptase, indicating that heterophilic antibodies were present that caused a 
falsely elevated serum tryptase. HBT treatment decreased the levels of Hama to amounts 
below (or borderline above) the detection limit of the Hama assay; in contrast, there 
was no significant difference (p = 0.094) between total IgE in sera before and after HBT 
treatment.
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ABSTRACT
Background There is no single reliable test for diagnosing autoimmune 
pancreatitis (AIP) and differentiating this disease from other disorders. Several 
serological markers have been proposed but most of these lack sufficient 
validation.
Objective To determine the diagnostic value of autoantibodies (antinuclear 
antibody/ANA, rheumatoid factor/RF, anti carbonic anhydrase II/ACA II, anti 
lactoferrin/ALF, perinuclear anti neutrophil cytoplasmic antibody/p-ANCA, 
extractable nuclear antigens/ENA) in groups of patients with AIP, various benign 
and malignant pancreatobiliary diseases and Sjögren’s syndrome. In comparison 
we also determined the diagnostic test characteristics of serum IgG, IgG 
subclasses, IgE and Ca 19 - 9. 
Design Prospective single-center study. Inclusion of consecutive patients 
presenting with AIP (n=33), pancreatic carcinoma (n=53), cholangiocarcinoma 
(n=32), chronic pancreatitis (n=30), PSC (n=30) and Sjögren’s syndrome 
(n=31). Diagnostic characteristics and optimal cut-off levels were assessed to 
differentiate between AIP and malignancy. Logistic regression was performed to 
detect combinations of tests that predict AIP. 
Results The seroprevalence of ANA, RF, ACA II and ALF was low and 
overall comparable for AIP, chronic pancreatitis, pancreatic cancer and 
cholangiocarcinoma. None of the tested autoantibodies was found to be 
discriminative or diagnostically helpful. IgG4 was the best single diagnostic test 
(AUC 0.89). The optimal cut-off level was 2.8 g/L (2 x upper limit of normal). 
Combination of IgG4, IgG3 and Ca 19 - 9 predicts probability of AIP with an AUC 
of 0.93.
Conclusions Testing for autoantibodies did not appear to be clinically useful 
in the diagnosis of AIP in this Western population. IgG4 was confirmed to be the 
best single test to differentiate between AIP and malignancy, with an optimal 
cut-off level of twice the upper limit of normal. Combining IgG4, IgG3 and Ca 
19 - 9 can be used to reliably predict a diagnosis of AIP.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is a distinct fibroinflammatory disease of the 
pancreas that is characteristically responsive to corticosteroids.1-2 Currently 
two types of AIP are recognized. Type 1 AIP is a manifestation of IgG4 related 
disease, type 2 has substantial clinical overlap with type I, but is characterized 
by normal IgG4 levels and distinctive pathological features.3 In its classical 
form, the disease presents like pancreatic carcinoma. Extrapancreatic 
biliary involvement may be prominent, resembling cholangiocarcinoma or 
primary sclerosing cholangitis. Other extrapancreatic manifestations include 
retroperitoneal fibrosis and sialoadenitis, mimicking Sjögren’s syndrome.4 The 
pathogenesis of AIP is not completely understood. The current understanding 
is that in genetic susceptible persons,5-6 an autoimmune reaction (Th1 
mediated) to auto antigens, or infectious agent (H pylori7-10) triggers a Th2 
mediated (allergic) response which leads to excessive or inappropriate B cell 
activation.11-14 It is not known whether IgG4 (or IgG4-immune complexes), 
classically known as an anti-inflammatory globulin, is pathogenic or an 
epiphenomenon.15
A large number of serological markers such as IgG4,16-22 total IgG,16-20, 23-27 
and the presence of autoantibodies such as antinuclear antibody (ANA),20, 28-34 
rheumatoid factor (RF),20, 29-30, 32-33, 35-37 anti carbonic anhydrase II (ACA II)30, 32-33, 38-42 
and anti lactoferrin ( ALF)30, 32, 43 have been proposed as useful diagnostic tests 
(supplementary Table 1). Although it has become clear that IgG4 is the best 
single marker of AIP, levels may be normal in otherwise characteristic AIP 
and may be elevated in other conditions including PSC and pancreatic cancer. 
The diagnostic significance of autoantibodies has not been well defined. 
Nevertheless the presence of autoantibodies forms one of the components of 
several (Asian, Japanese)44 but not all (HISORt,45-46 International Consensus47) 
diagnostic criteria systems developed for diagnosing the disease. The superiority 
of one of these systems over the other has not been established.
Given these uncertainties the primary aim of the present study was to assess 
the seroprevalence and diagnostic value of a set of previously proposed 
autoantibodies in a population of Western AIP patients and in groups of patients 
with disorders that may mimic or are associated with AIP. A secondary aim 
was to compare the diagnostic significance of these antibodies with that of 
measuring IgG, IgG subclasses, IgE and tumor marker Ca 19 - 9.
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METHODS
PATIENT SELECTION
Between March 2007 and May 2011 sera were obtained from consecutive 
individuals presenting with AIP, pancreatic carcinoma, cholangiocarcinoma, 
chronic (alcoholic, obstructive or idiopathic) pancreatitis and primary sclerosing 
cholangitis. Serum aliquots of patients with Sjögren’s syndrome were obtained 
from an existing serum bank. After written informed consent was obtained, 
sera were collected together with samples drawn for routine clinical analysis 
and processed immediately or stored at -80°C. The diagnosis of AIP was 
established according to the International Consensus Diagnostic Criteria,47 
Asian,44 or HISORT45-46 criteria, a combination of unexplained pancreatic disease, 
biliary disease/extrapancreatic manifestations and either response to steroids 
or IgG4-positive serology.48 These diagnostic criteria were also systematically 
applied to all chronic pancreatitis cases to exclude misclassification. All cases 
with pancreatic carcinoma and cholangiocarcinoma were histologically 
confirmed. PSC and Sjögrens syndrome were diagnosed according to accepted 
criteria.49-50
LABORATORY INVESTIGATION
The following laboratory investigations were performed: measurement of 
immunoglobulins total IgG, IgG subclasses 1 to 4 and IgE and the presence of 
the autoantibodies ANA, RF, pANCA, Extractable Nuclear Antigen (ENA) aSSa 
and aSSb, ACA II and ALF. We also included the tumor marker Ca 19 - 9 as high 
levels are considered indicative of malignancy.51-53 Finally we developed a test 
to detect anti (pancreatic) elastase antibodies (AE). Commercially available tests 
were used for IgG and IgG subclasses, IgE, ANA, RF, pANCA, ENA (aSSa and 
aSSb) and Ca 19 - 9. For ACA II, ALF and AE, ELISA’s were developed in a uniform 
matter. For a detailed description of each test, see Supplementary File 1.
STATISTICAL ANALYSIS
Frequencies of positive tests were determined in each group. One way analysis 
and pair wise comparisons with Bonferroni correction for multiple testing 
were performed to detect significant differences between groups. Diagnostic 
characteristics of each test were calculated using 2x2 tables: sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), 
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likelihood ratio of positive test (LR+) and likelihood ratio of negative test (LR-). 
Receiver operating curves (ROC) were constructed to assess optimal cut-off 
levels and calculate the area under the ROC curve (AUC). Logistic regression 
was performed to detect combinations of tests that predict AIP. Statistical 
analysis was carried out using SPSS Statistics 17.0 Software (IBM, New York, 
USA). Two-sided p-values ≤ 0.05 were considered statistically significant.
ETHICAL CONCERNS
The study was approved by the institutional review board of the Erasmus 
University Medical Center, Rotterdam, the Netherlands.
RESULTS
The patient groups differed significantly in terms of age, sex and bilirubin level 
(Table 1), but these differences were not attributable to differences between 
AIP and control groups. AIP patients were mainly type 1. Proximal biliary 
involvement was noted in 50%, 28% were on low dose maintenance prednisone 
(2.5 - 10 mg/d).
The seroprevalence of antibodies previously proposed as indicative for AIP, 
in particular ANA, RF, ACA II and LF, was low and overall comparable for patients 
with AIP, chronic pancreatitis, pancreatic cancer and cholangiocarcinoma. 
No significant differences between the study groups were detected. Only few 
cases with anti elastase antibodies were found, and this test was not found 
Table 1 Patient characteristics
AIP Pancreatic
carcinoma
Cholangio-
carcinoma
Chronic
pancreatitis
PSC Sjögren’s 
syndrome
p-overall
Number 33 53 32 52 30 31
Age (yr) 65 (55 - 73) 66 (60 - 71) 66 (57 - 73) 52 (44 - 60) 46 (40 - 53) n.a. < 0.0011
Male (n,%) 28 (85%) 27 (51%) 15 (47%) 36 (69%) 23 (77%) 3 (10%) < 0.0012
bilirubin 
(μmol/L)
10(8 - 34) 15(9 - 57) 23(8 - 57) 7(5 - 11) 38(15 - 109) 0(0 - 1) < 0.0011
Age and laboratory tests in median (interquartile range). AIP: autoimmune pancreatitis, 
PSC: primary sclerosing cholangitis, n.a: not available. 1one way analysis of variance to 
detect differences between groups, with p< 0.05 between AIP and group (post hoc paired 
test with correction for multiple testing) 2Fisher’s exact test
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Figure 1 Immunoglobulin G, IgG subclasses, IgE and Ca 19 - 9 in AIP, other 
pancreatobiliary diseases and Sjögren’s syndrome
Box plot. The box shows the median value and the interquartile (25 to 75 percentile)
range, the whiskers the range of the upper and lower quartile with the minimal and
maximal values. *p< 0.05 between AIP and group. CP=chronic pancreatitis,
PAC=pancreatic carcinoma, CC=cholangiocarcinoma, AIP=autoimmune pancreatitis,
PSC=primary sclerosing cholangitis, SS=Sjögren’s syndrome. IgG2 is not shown, no
significant differences were detected.
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to be discriminative. Lactoferrin antibodies and pANCA were more frequent in 
primary sclerosing cholangitis. ANA, RF IgM and aSSa and aSSb were indicative 
of Sjögren’s syndrome.
IgG, IgG1, IgG3, IgG4, IgE and Ca 19 - 9 levels significantly differed between 
AIP and malignancy (Figure 1, Supplementary Table 2). The most striking 
difference between AIP and the other groups was the IgG4 level. IgE levels were 
also significantly higher in AIP but there was noticeable overlap with other 
patient groups. In patients with pancreatic cancer and cholangiocarcinoma the 
highest Ca 19 - 9 levels were found but substantially elevated levels were also 
frequently observed in AIP and PSC. The diagnostic performance of each single 
test in differentiating between AIP and malignancy is shown in Table 3.
IgG4 was the best single test to discriminate between AIP and malignancy, with 
an AUC of 0.89, followed by IgG3 (0.76), Ca 19 - 9 (0.76), IgE (0.75), IgG (0.74) 
and IgG1 (0.70). The highest likelihood ratios for positive test (LR+, tests that 
rule in AIP with respect to malignancy) were found for IgG3 > 1.1 g/L (LR+ 91), 
IgG4 > 2.8 g/L (LR + 26.9), and the presence of elastase antibodies (LR+ 30.5). 
The sensitivity of IgG3 levels > 1.1 g/L and the presence of elastase antibodies 
however, was extremely low (18.2 and 6.1% respectively). The lowest likelihood 
ratios for negative tests (LR-, tests that rule out AIP with respect to malignancy) 
were IgG4 < 1.4 g/L (LR- 0.21), IgG4 < 2.8 g/L (LR- 0.36), IgE < 155 kU/L 
(LR - 0.41) and IgG2 < 6.4 g/L (LR- 0.43).
The optimal cut-off level of IgG4 is 2.8 g/L, that is twice the upper limit of 
normal (Table 4). Although the sensitivity of a cut-off level of 1.4 g/L, which is 
Table 4 Optimal cut-off levels of IgG (subclasses), IgE and Ca 19 - 9 for differentiating 
between AIP and malignancy
Normal range Optimal
cut- off level
Sensitivity (%) Specificity (%)
IgG (g/l) 7.0 - 16.0 10.6 75.8 64.7
IgG1 (g/l) 4.9 - 11.4 6.8 66.7 69.4
IgG3 (g/l) 0.20 - 1.10 0.37 81.8 59.5
IgG4 (g/l) 0.08 - 1.40 2.80 g/l 64.5 97.6
IgE (kU/l) n.a. 155 kU/l 66.7 81.4
Ca 19.9 (kU/L) 0 - 34 70* 70.6 75.0
*Levels lower than 70 U/ml are indicative of AIP, n.a.: not available.
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the generally accepted upper limit of normal, is higher (83.9%), the specificity 
of IgG4 levels > 1.4 g/L is quite low (77.6%).
The result of the logistic regression analysis is shown in Figure 2 and 
Supplementary File 2. Combining IgG4, IgG3 and Ca 19 - 9 levels predicts 
probability of AIP with an AUC of 0.93, which is better than for IgG4 alone.
DISCUSSION
The results of the present study indicate that testing for autoantibodies such as 
ANA, RF, ACA II and ALF is not useful in diagnosing AIP, at least not in a Western 
patient population. This study confirms that IgG4 remains the single most 
important diagnostic laboratory test, with an optimal cut-off level of twice the 
upper limit of normal.
In previous studies, mainly performed in Asia, substantial higher frequencies of 
positive tests for ANA, RF, ACA II and ALF in AIP were reported.20, 28-33, 35-43 As in 
both these series and in our study the large majority of patients were classified 
Figure 2 Combination of IgG4, IgG3 and Ca 19 - 9 in discriminating between AIP and 
malignancy ROC curves of Ca 19 - 9, IgG3 and IgG4 are shown as single test and as 
predicted probability of AIP (logistic regression analysis).
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as type I, differences in AIP subtype do not readily explain the diverging results. 
Possibly these could be related to different genetic background of the study 
populations. Further it may be possible that laboratory technical issues could 
at least partially be involved in explaining different outcomes. This could be 
subject for further research.
Obviously, based on our results testing for autoantibodies cannot be advocated 
in the workup of patients possibly suffering from AIP, or for differentiating AIP 
from other benign and malignant pancreatobiliary disorders. The results further 
suggest that systems developed for assisting in the diagnosis, in particular 
the Japanese and the Asian consensus criteria should be modified with respect 
to the presence or absence of detectable autoantibodies, at least when used 
in non-Asian populations. Other proposed diagnostic systems, such as the 
HISORt and the International consensus criteria, do not include the presence 
of autoantibodies. Our findings strongly support the major diagnostic weight 
given to elevated serum IgG4 levels in these systems. In line with previous 
reports17 we confirm that IgG4 levels higher than twice the upper limit of 
normal clearly suggest a diagnosis of AIP. In clinical practice elevated but lower 
(intermediate) levels should be interpreted with great caution as the specificity 
of this finding is suboptimal. This study found that, in addition to IgG4, total 
IgG, IgG1, IgG3, IgE and Ca 19 - 9 levels also differed significantly between 
AIP and malignancy. However, their test characteristics are insufficient to be 
regarded as useful single diagnostic tests. The combination of IgG4, IgG3 and 
Ca 19 - 9 predicted probability of AIP with an AUC of 0.93, which was better 
than IgG4 alone. The concept of combining these tests to improve diagnosis is 
attractive, since they are readily available. However, it was a result of logistic 
regression analysis (Formula available at Supplementary file 2) and should not 
be interpreted as combining three single tests with their respective cut-off 
values. The value of this combination test needs to be addressed in a validation 
study.
As far as we are aware this is one of the few studies addressing the diagnostic 
value of antibody testing in AIP. This was a prospective study not only including 
patients with a definitive diagnosis of AIP but also a number of relevant and 
well defined reference groups. In all cases with malignancies diagnosis was 
histologically confirmed. Follow up of AIP patients was sufficient enough to 
exclude malignancy (at least 2 years). A limitation is that the results apply to 
a Western patient population and may not be applicable to other populations. 
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The use of diagnostic criteria as a selection criterion for AIP (which include 
IgG, IgG4 and autoantibodies) may have introduced selection bias. Also the 
results were derived from a population of largely AIP type 1 patients and may 
not necessarily apply to AIP type 2. Further, although we sincerely attempted to 
include all consecutive AIP patients, the number of cases is moderate, reflecting 
the relative rarity of the disease. Finally, 28% of AIP patients were on low dose 
maintenance prednisone (2.5 - 10 mg/d), which may have lowered levels of 
immunoglobulins or autoantibodies. However, although steroid therapy has 
shown to lower IgG4 levels, they usually still remain elevated despite remission. 
In a previous study, the sensitivity of IgG4 did not change significantly when 
AIP patients with steroid treatment were excluded.17 In our study, results on 
autoantibodies did not differ between patients with or without prednisone.
For diagnostic purpose testing for autoantibodies including ANA, RF, ACA II 
and ALF is not useful. What this means for their putative role in pathogenesis 
remains unclear. Generally, autoimmunity is still considered the major trigger 
of inflammatory cascade in AIP. However, accumulating evidence suggests that 
allergic (Th2 mediated) reactions play an important role in the pathogenesis of 
AIP.15,55 Generally, IgG4 can be induced by repeated antigen exposures and is 
controlled, like IgE production, by Th2 cells. Whether the causal antigen in AIP 
is endogenous or exogenous, still remains to be elucidated. In any case, with 
its male predominance and striking sensitivity to steroids, AIP clearly does not 
meet the classical phenotype for autoimmune disease.
In conclusion, this study shows that testing for autoantibodies, previously 
proposed to be of diagnostic value, is not useful in the workup of patients with 
a possible diagnosis of AIP. IgG4 is the best single test to differentiate between 
AIP and other pancreaticobiliary disorders, with an optimal cut-off level of 2.8 
g/L (twice the upper limit of normal).
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SUPPLEMENTARY MATERIAL
SUPPLEMENTARY FILE 1: SEROLOGIC TESTS
Immunoglobulines
IgG and IgG subclasses were determined on the Immage 800 Analyzer 
(Beckman Coulter, Mijdrecht, the Netherlands) using Peliclass IgG subclass 
nephelometry kit according to manufacturer’s instructions (Sanquin, 
Amsterdam, the Netherlands). The upper limits provided by the manufacturer 
were 16.0 g/L (IgG), 11.40 (IgG1), 6.40 (IgG2), 1.10 (IgG3) and 1.40 (IgG4) g/L. 
Total IgE was determined on the ImmunoCAP 250 system, according to the 
manufacturer’s instructions (Phadia, Nieuwegein, the Netherlands). No upper 
limit was given, results in kU/L.
Ca19 - 9
Serum Ca 19 - 9 levels were measured using an electrochemiluminescense 
immunoassay (ECLIA) on a Modular Analytics E module (Roche Diagnostics Co, 
Tokyo, Japan). The upper limit provided by the manufacturer was 34 U/mL.
Autoantibodies: immunofluorescence
ANA were determined by routine laboratory indirect immunofluorescence 
technique using Hep-2000 slides (Immuno Concepts, N.A. Ltd, Sacramento, 
California). As cut off value titer 80 was used. ANCA were also determined by 
indirect immunofluorescence according daily routine of the laboratory. Ethanol 
Fixed Human Neutrophil Slides ( IgG) were used for screening and positive 
results were confirmed on Formalin Fixed Human Neutrophil slides ( IgG) (both 
provided by INOVA Diagnostics, Inc, San Diego, California). A cut-off titer of 10 
on Ethanol slides, and 20 on formalin slides was used, respectively.
Autoantibodies: ELISA
RF IgM was determined by an in-house ELISA which is used in the daily routine 
laboratory diagnostics.
Alle sera were screened for the presence of ENA by QUANTA LiteTM ENA 6 ELISA 
kit IgG (INOVA Diagnostics, Inc, San Diego, California). If this screening test was 
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positive, several tests were performed to confirm the presence of anti-SS-A and/
or anti-SS-B antibodies: QUANTA LiteTM SS-A/SS-B (ENA) ELISA Kit IgG (INOVA 
Diagnostics, Inc, San Diego, California), ANA Profile 3 Line blot IgG (EuroImmun, 
Lubeck, Germany), EliA Ro/ La IgG (Phadia, Uppsala, Sweden) and INNO-LIA ANA 
Update (Innogenetics NV, Gent, Belgium. Two positive results were concerned as 
a positive test for one of these antibodies.
ACA II, ALF and AE: home made ELISA
Because no commercial tests were available, ACAII, ALF and AE were tested 
in a homemade ELISA. High binding plastic micro titer plates (Greiner 
Bio-one, Netherlands) were coated with CAII (Sigma-Aldrich, Germany), 
E (Calbiochem,Netherlands) or LF (Sigma-Aldrich, Germany , all 1 mg/
ml) in NH4HCO3 (0.1M) at 37°C overnight. After washing three times with 
PBS/0.05% Tween 20 wells were blocked with 0.3% casein overnight at room 
temperature. After washing three times serum samples and controls (diluted 
1:100 in Trisbactopepton/0.05% Tween 20) were incubated for 1 hour at 37°C. 
The microtiter plates were washed thoroughly with PBS 0.05%Tween and 
incubated another hour at 37°C with anti-human-IgG peroxidase (home made) 
diluted 1:100 in Trisbactopepton/Tween 20. After washing the substrate buffer 
was applied for 30 minutes, after which stop solution (H2SO4) was added. 
The optical density (OD) was read at 450 nm. OD values exceeding 2SDs of the 
reference material from healthy blood donors( n=100) were considered positive.
SUPPLEMENTARY FILE 2: PREDICTED PROBABILITY
The probability of AIP can be predicted using the following formula:
Probability of AIP = -0.39 + 2.45 ∙ IgG3 + 3.55∙(log IgG4) - 1.24 (log Ca19 - 9)
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Supplementary Table 1 Reported seroprevalence of abnormal IgG, IgG4 and IgE levels 
and of autoantibodies in AIP and other pancreatobiliary diseases, Sjögren’s syndrome and 
healthy controls
AIP PAC CC CP PSC SS Control Reference
Elevated 
IgG4
68 - 95% 0 - 10% 13.5% 0 - 15% 0 - 36% 0% 2 - 5% 16-22
Elevated IgG 37 - 80% 3 - 5% - 1 - 10% 30% - 10% 16-20, 23-27
Elevated IgE 35%-77% 0% - - - - - 54-55
ANA 43 - 80% - - 6% - 30 - 90% 4% 20, 28-33
RF 13 - 30% - - 0% - 75 - 95% 3 - 25% 20, 29-33, 35-37
aSSa 0 - 2% - - - - 70 - 100% 0% 20, 28, 31
aSSb 0 - 2% - - - - 60 - 100% 0% 20, 28, 31
pANCA - - - - 30 - 80% - 0% 28, 56-57
ACA II 10 - 89% 0% - 0 - 46% - 62 - 68% 0 - 10% 30, 32-33, 38-42
ACA IV 27% 14% - 13% - 45% - 41
ALF 23 - 76% - - 0% - - - 30, 32, 43
aPSTI 31% 0% - 0% - - 0% 30, 58
AMY-2A 100% 0% - 0% - - - 59
aHSP10 92% 8% - 8% - - - 60
aPBP 94% 5% - 0% - - 0% 7
AIP=autoimmune pancreatitis, PAC= pancreatic adenocarcinoma, C=cholangiocarcinoma, 
CP=chronic pancreatitis, PSC=primary sclerosing cholangitis, SS=Sjögren’s syndrome. 
ANA=antinuclear antibody, RF=rheumatoid factor IgM, aSSa/b=anti-R0 and anti-La 
antibody associated with Sjögren’s syndrome, pANCA=perinuclear anti neutrophil 
cytoplasmic antibody, ACA= carbonic anhydrase antibody, ALF= lactoferrin antibody, 
aPSTI=pancreatic secretory trypsin inhibitor antibody, AMY-2A=amylase alpha-2A 
antibody, aHSP10=heat shock protein antibody, aPBP=plasminogen binding protein 
antibody
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ABSTRACT
Objective To compare efficacy of high versus low doses of prednisone for 
induction of remission in AIP. 
Methods This is a retrospective, multicenter study including patients 
diagnosed with AIP between May 1992 and August 2011. Clinical, laboratory 
and imaging findings were assessed before treatment and at 1, 3 and 6 months 
after starting treatment. 
Results A total of 65 patients (57 males; median age 63 years) were treated 
with an initial dose of prednisone of 10 mg/d (n=5), 15 mg/d (n=2), 20 mg/d 
(n=7), 30 mg/d (n=15), 40 mg/d (n=34), and 60 mg/d (n=2). There were no 
significant differences in baseline characteristics between the treatment groups 
including age, presenting symptoms and laboratory results. During a follow-up 
period of 6 months all patients responded clinically well. After 6 months, 
treatment response with respect to symptomatic, radiological and laboratory 
improvement was comparable for the different dosage groups. 
Conclusions In patients presenting with AIP no evidence was found for 
a superior treatment effect of high-dose prednisone compared with low-
dose (≤ 20 mg/d) treatment. Based on these retrospective data the general 
recommendation to start with high-dose therapy may be reconsidered.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is a distinct type of chronic pancreatitis, 
predominantly affecting males in their fifth and sixth decade. Frequently AIP 
represents the pancreatic manifestation of IgG4-related disease, a systemic 
disorder that may not only involve the pancreas but almost any other organ. 
Patients frequently present with obstructive jaundice, weight loss, steatorrhea 
and diabetes mellitus. Characteristic radiological features include diffuse 
enlargement of the pancreas and irregular narrowing of the main pancreatic 
duct. Laboratory tests often reveal elevated serum levels of IgG and/or IgG4.1 
Histologically, AIP is frequently associated with a lymphoplasmacytic infiltration 
rich of IgG4-positive plasma cells and fibrosis of the pancreatic parenchyma.2 
Unlike other types of pancreatitis, AIP responds dramatically to steroid 
therapy.3-7 The usually recommended dosage of prednisone (or equivalent 
dosage of prednisolone) for remission induction is 0.6 mg/kg/d, resulting in 
daily starting doses of 30 - 40 mg.8-9 This recommended dosage is largely based 
on empirical data but lacks a solid scientific basis. Corticosteroid treatment, in 
particular when high doses are used, is potentially associated with significant 
side effects.10-13 These negative treatment effects may even be more important 
in patients presenting with AIP since this is a population characterized by 
relatively advanced age, (de novo) diabetes mellitus and obstructive jaundice. 
Further, the rationale for high-dose treatment could be questioned considering 
the well-established sensitivity of AIP to corticosteroids. We therefore 
investigated the efficacy of treatment in AIP patients using low (≤ 20 mg), 
medium (30 mg) and high (≥ 40 mg) daily doses of prednisone remission 
induction therapy.
MATERIALS AND METHODS
PATIENTS AND TREATMENT
A retrospective, multicenter study was conducted among patients diagnosed 
with AIP between May 1992 and March 2012. Data were retrieved from 
electronic medical record systems and by reviewing paper hospital 
charts. Patients were included if they fulfilled the ICDC, Asian or HISORt 
diagnostic criteria for AIP, or if diagnosis could be based on post-surgery 
histology, a combination of unexplained pancreatic disease, biliary 
disease/extrapancreatic manifestations and either response to steroids or IgG4-
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positive serology, and had been treated with prednisone as remission induction 
therapy.7,14-15 Patients were excluded if: 1. essential data with respect to the 
dose and duration of treatment and the evolution of symptoms, radiological 
abnormalities and laboratory findings were not available; 2. they had previously 
been treated with corticosteroids for the same condition; 3. concurrent 
initial treatment with azathioprine or other immunomodulating agents was 
instituted; 4. when biliary stents were still in place 6 months following the 
start of treatment, to exclude confounding by biliary drainage on clinical and 
biochemical response.
Data regarding induction of remission by steroid treatment were collected 
immediately before starting treatment (maximal allowed period 4 weeks) 
and subsequently after 1, 3 and 6 months. Additionally, data on concurrent 
biliary drainage, timing of stent removal and other immunosuppressive drugs 
which were initiated during the follow-up period were analyzed. Symptomatic 
response was defined as the disappearance of the initial clinical symptoms. 
Radiological response was defined as marked improvement or resolution of 
the pancreatic and/or extrapancreatic manifestations on imaging studies, 
particularly pancreatic swelling and pancreatic and biliary duct strictures. 
Relapse was defined as recurrence of disease after discontinuation of steroid 
therapy.
LABORATORY EVALUATION
The following laboratory parameters were analyzed: serum levels of 
immunoglobulin-G4 (IgG4), immunoglobulin-G (IgG), total bilirubin, 
alkaline phosphatase (ALP), aspartate aminotransferase (ASAT) and alanine 
aminotransferase (ALAT).
IMAGING
Initially patients were examined by contrast-enhanced computed tomography 
(CT), magnetic resonance imaging (MRI), and/or endoscopic retrograde 
cholangiopancreatography (ERCP). Morphological changes after steroid therapy 
were studied with CT and MRI or ERCP.
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STATISTICAL ANALYSIS
Patients were categorized into three prednisone dosage groups (low dose: 
10 - 20 mg/d, medium dose: 30 mg/d and high dose: 40 - 60 mg/d).
Statistical analysis was performed using Fisher’s exact test and Kruskall-Wallis 
test using SPSS 17.0 to compare baseline characteristics between patients 
treated with different doses of prednisone.
Differences in symptomatic and radiologic response between groups treated with 
different initial doses of prednisone were compared using Fisher’s exact test.
Differences in biochemical response between the treatment groups were 
compared in a repeated measurement model with a random intercept and 
random decline from baseline to month 1 and a random linear decline from 
month 1 and onwards to month 6. This broken stick model was used to 
describe the observed changes in the two described periods. The random 
intercept allows for adjustment of the individual baseline biochemical values.
To correct for multiple testing, a p-value < 0.01 was considered statistically 
significant.
MEDICAL ETHICAL CONCERNS
The study was approved by the Institutional Review Board of the Erasmus 
University Medical Center, Rotterdam, The Netherlands.
RESULTS
PATIENTS
A total of 65 patients with AIP (57 males and 8 females with a median age 
of 63 years) were included (Figure 1). A recent onset of diabetes mellitus 
(< 1 year) was seen in 24/65 (38%) patients. Extrapancreatic manifestations 
were observed in 48/65 (74%) patients, including extrapancreatic sclerosing 
cholangitis in 38/65 (59%) cases. Table 1 provides a further overview of 
demographic data and clinical symptoms. No patients were lost to follow-up 
during the six months study period.
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Five patients were treated with an initial dose of prednisone of 10 mg/d, 
2 patients with 15 mg/d, 7 patients with 20 mg/d, 15 patients with 30 mg/d, 
34 patients with 40 mg/d and 2 patients with 60 mg/d (Table 2). The mean 
prednisone induction dosage in the low dose group (10 - 20 mg) was 0.22 mg/
kg/d, in the medium dose group (30 mg) was 0.41 mg/kg/d and in the high 
dose group (40 - 60 mg) was 0.55 mg/kg/d.
There were no significant differences in baseline characteristics including 
gender, age, presenting symptoms, laboratory and imaging results between the 
treatment groups (Table 1). In general, the initial dose was administered for 2 - 4 
weeks and gradually tapered by 5 mg every 2 weeks. In patients treated with 
10 - 20 mg/d, the initial dose was maintained for a longer period. During the 
follow-up period, the dose of prednisone was not raised in the low-dose group. 
At the time when prednisone was started 28/65 (43%) patients were treated 
for distal biliary obstruction by endoscopic insertion of plastic endoprotheses: 
6/14 patients (43%) in the low-dose group, 5/15 (33%) in the medium-dose 
group and 17/36 (47%) in the high-dose group. These stents were removed 
after a median of 10 weeks (IQR 5 - 15) weeks.
During the follow-up period of 6 months, azathioprine was added to steroid 
therapy in 12/65 (18%) patients: 6/14, 1/15 and 5/29 in the low-, medium- and 
high-dose group, respectively. Seven of the 12 (58%) patients who were treated 
with azathioprine took this drug during at least two months. The number of 
Figure 1 Study enrollment and exclusion.
AIP indicates autoimmune pancreatitis.
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patients treated with azathioprine during the 6 months follow-up period did not 
differ between the treatment groups (p=0.038).
CLINICAL RESPONSE
During a clinical follow-up period of 6 months, 59 (92%) of 65 patients 
achieved complete clinical response, while in 5 (8%) the response was partial. 
The regression of clinical symptoms after 6 months of treatment was not 
associated with the dosage of prednisone (p=0.999) (Figure 2). During the 
6 month follow-up period, all patients in the low-dose group continued 
prednisone treatment in contrast to 12/15 and 20/36 in the medium- and 
high-dose group, respectively (p=0.003). No relapses were observed in those 
patients in whom prednisone was discontinued.
Table 2 Steroid remission induction therapy
Dose prednisone (mg/d) No. of patients Treatment group
10 5 Low
15 2 Low
20 7 Low
30 15 Medium
40 34 High
60 2 High
Figure 2 Symptomatic response after 6 months of prednisone remission induction 
therapy. Results were categorized in 3 treatment groups, low dose (10 - 20 mg/d), 
medium dose (30 mg/d) and high dose (40 - 60 mg/d) prednisone.
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BIOCHEMICAL RESPONSE
Before steroid therapy was started, elevated levels of serum IgG (> 18 g/L) 
and IgG4 (> 1.4 g/L) were observed in 42% and 77% respectively. After start 
of treatment, IgG normalized in all patients. IgG4 showed a rapid decline in 
the majority of patients, but levels remained elevated in 76% (Figure 3A). 
Figure 3 Biochemical mean response during 6 months of prednisone remission induction 
therapy: IgG4 (A), IgG total (B), Total Bilirubin (C), Alkaline Phosphatase (D), ASAT (E), 
ALAT (F). ── low dose (10 - 20 mg/d), −− medium dose (30 mg/d) and ∙∙∙∙ high dose 
(40 - 60 mg/d) prednisone.
IgG4 indicates immunoglobulin-G4; IgG, immunoglobulin-G; ALP, alkaline 
phosphatase; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase.
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At baseline the majority of patients had abnormal serum liver tests. 
In conjunction with clinical improvement, in all patients rapid declines in total 
bilirubin, alkaline phosphatase, ASAT and ALAT were observed, which persisted 
after stent removal (Figure 3C-F).
Treatment response as assessed by biochemical parameters was not associated 
with doses of prednisone (Table 3). Although the quantitative decrease in IgG 
and IgG4 levels in the low-dose group was more pronounced, no significant 
differences were observed at 6 months (p=0.131, p=0.234).
RADIOLOGICAL RESPONSE
Before treatment diffuse pancreatic enlargement was observed in 37/63 (59%) 
patients and focal pancreatic enlargement in 18/63 (29%). In 22/31 (71%) patients, 
ERCP or MRI showed diffuse narrowing of the main pancreatic duct (MPD), whereas 
in 3/31 (10%) segmental narrowing of the MDP was observed. After 6 months of 
steroids, all patients showed partial (19 patients, 42%) or complete (26 patients, 
58%) resolution of pancreatic or biliary abnormalities on imaging studies.
Table 3 Response to treatment during 6 months of treatment. Estimated mean decline 
the first month and from month 1 to month 6 by dosage.
Biochemical 
Response
Low
0 - 1mo (95%CI)
1 - 6mo (95% CI)
Medium
0 - 1mo (95%CI)
1 - 6mo (95% CI)
High
0 - 1mo (95%CI)
1 - 6mo (95% CI)
p-value
IgG4 (g/L) -4.28 (-7.34; -1.22)
-0.58 (-0.90; -0.25)
-3.30 (-6.87; 0.27)
0.22 (-0.30; 0.73)
-3.49 (-5.44; -1.53)
-0.05 (-0.35; 0.25)
0.85
0.03
IgG (g/L) -8.15 (-11.29; -5.00)
-0.74 (-1.14; -0.35)
-7.17 (-11.97; -3.36)
0.03 (-0.43; 0.49)
-5.48 (-7.68; -3.28)
0.13 (-0.29;0.54)
0.34
0.01
Total bilirubin 
(µmol/L)
-84.8 (141.5;-28.2)
-1.21 (-3.19; 0.77)
-91.0 (-147.6; -34.4)
-2.10 (-4.20; 0.01)
-73.1 (-109.0; -37.2)
-1.60 (-3.07; -0.14)
0.84
0.82
Alkaline 
Phosphatase 
(U/L)
-363 (-491; -234)
-16.5 (-30.3; -2.58)
-294 (-422; -166)
-15.4 (-30.8; -0.02)
-263 (-345; -181)
-11.4 (-22.0; -0.81)
0.42
0.82
ASAT (U/L) -101.6 (-167.8;-35.4)
-2.49 (-7.52; 2.54)
-87.4 (-149.6; -25.2)
-0.57 (-5.92; 4.77)
-106.7 (-146.8;-66.6)
0.85 (-3.13; 4.83)
0.87
0.57
ALAT (U/L) -117.1 (-235.9; 1.73)
-5.16 (-14.09; 3.76)
-160.0 (-279.5;-40.3)
-5.71 (-15.57; 4.15)
-158.2 (-234.1;-82.4)
-6.18 (-13.09; 0.72)
0.82
0.98
* adjusted for baseline biochemical values in a repeated measurement model with a 
random intercept and random decline from baseline to month 1 and a random linear 
decline from month 1 and onwards to month 6 (broken stick model y= a+b*t+c(t-1), 
t=months y=lab value). ** p < 0.01. IgG4 indicates immunoglobulin-G4; IgG, 
immunoglobulin-G; ALP, alkaline phosphatase; ASAT, aspartate aminotransferase; ALAT, 
alanine aminotransferase.
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DISCUSSION
This study shows comparable therapeutic efficacy over a range of prednisone 
induction doses in AIP. Importantly, no evidence was found for an inferior 
treatment effect of low (10 - 20 mg/d) prednisone as compared to high 
(40 - 60 mg/d) prednisone.
The therapeutic efficacy of corticosteroid in AIP has been well documented3-7 
but we are not aware of previous studies specifically addressing different 
corticosteroid remission induction regimes. In a number of studies not primarily 
aimed to evaluate dose-response relationships, comparable outcomes were 
reported for patients treated with medium to high doses of prednisone, ranging 
from 25 to 50 mg/d.9,16-18 Reports on corticosteroid induction doses lower 
than 15 mg/d are scarce. One case report described successful treatment with 
prednisolone 5 mg/d.19 Although worsening of glycaemic control is a known 
side effect in the elderly diabetic AIP patient, steroid therapy has been reported 
to improve endocrine pancreatic function in approximately half of the patients. 
Yet this beneficial effect is counterbalanced by newly developed diabetes 
or worsening of diabetic control in a substantial subset of patients.6,17,20-21 
High-dose steroid therapy, especially during an extended period (> 1 week), 
poses a substantial risk for significant side effects.10-13 Frequently observed 
important side-effects in elderly populations are inducing, or worsening of 
Figure 4 Radiological response after 6 months of prednisone remission induction 
therapy. Results were categorized in 3 treatment groups, low dose (10 - 20 mg/d), 
medium dose (30 mg/d) and high dose (40 - 60 mg/d) prednisone.
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pre-existing, diabetes mellitus, osteoporosis, opportunistic infections, cataract 
and psychological disturbances. Diabetes mellitus or worsening of glycaemic 
control is frequent in individuals presenting with AIP.4,18,20,22 In a cohort of 114 
Dutch patients, 35% of patients had recent onset diabetes at presentation 
(unpublished data). Corticosteroids, in particular high doses, obviously have the 
potential to further impair glucose tolerance and glycaemic control. In series 
of elderly patients with rheumatoid arthritis and chronic kidney disease 9 - 40% 
developed diabetes mellitus upon treatment with steroids. Older age and 
obesity were identified as independent risk factors.11,12 Additionally, Gurwitz 
et al13 demonstrated with prednisone therapy a dose-related risk of developing 
hyperglycaemia requiring therapy with oral glucocorticoid use. The odds 
ratio for starting an oral hypoglycaemic agent or insulin ranged from 1.77 for 
patients treated with a hydrocortisone-equivalent dose of 1 - 39 mg/d, to 3.02 
for 40 - 70 mg/d and to 5.82 for 80 - 119 mg/d. Furthermore, high-dose steroids 
result in a greater risk of complicated glucocorticoid withdrawal and require 
longer periods of drug tapering. Any patient treated with at least 20 mg/d 
prednisone for more than 5 days is at risk of hypothalamic-pituitary-adrenal 
suppression.23
Our study has a number of limitations. This study had a retrospective, 
uncontrolled nature and had a limited number of patients treated with low 
initial doses of prednisone. Importantly, individual patient characteristics or 
disease manifestations might have influenced the treating physician to choose 
a particular corticosteroid dose. Nevertheless, as shown in Table 1, there 
were no significant differences in these baseline characteristics between the 
treatment groups. It is important to stress that patients included in this series 
were not treated according to a particular protocol but at the discretion of the 
treating physician. Most patients in the low dose group were recently treated by 
a single physician who believed, based on preliminary observations, that low 
dose prednisone could be as effective as higher doses in the initial treatment 
of the disease. In another center, however, the standard regimen was 30 or 40 
mg prednisone per day throughout the study period. Due to the retrospective 
design of this study we were not able to retrieve sufficient and/or reliable data 
for assessing potential adverse treatment effects e.g. on glucose tolerance, 
body weight and blood pressure.
Differences in biochemical response adjusted for baseline biochemical values 
were compared in a repeated measurement model with a random intercept and 
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random decline from baseline to month 1 and a random linear decline from 
month 1 and onwards to month 6. The broken stick model was used to take 
into account the structural changes of gradient between the first month of 
follow-up and the next 5 months (Figure 2).
Concurrent biliary drainage and azathioprine therapy are of concern in 
interpreting the results of this study. Pancreaticobiliary imaging after 2 weeks, 
using CT and/or ERCP, has been recommended to evaluate the response to 
corticosteroid treatment, in particular when this information is considered part 
of the diagnostic process.24 Since AIP often responds well to steroids, biliary 
stents are often removed at an early stage. Nevertheless, in clinical practice, 
the timing of stent removal varies substantially, as illustrated by the markedly 
variable period of stenting in our study. This implies that the observed response 
to treatment in the first three months was due to the combination of steroid 
treatment and biliary drainage. The percentage of patients treated with stents 
and the time to stent removal did not differ between the groups and all patients 
were free of biliary stents after 6 months. Therefore it seems unlikely that our 
main conclusions are invalidated by concurrent endoscopic treatment.
Steroid therapy is frequently combined with other types of immunosuppressive 
drugs. Following relapse or unsuccessful tapering of prednisone, azathioprine 
is often used in combination with steroids to maintain remission or as a 
corticoid-sparing immunosuppressant. We excluded patients initially treated 
with a combination of immunosuppressive drugs. Patients were not excluded 
when azathioprine treatment was introduced subsequently. Azathioprine was 
used in a minority of patients and usually after 3 - 4 months of prednisone 
treatment. Nonetheless, since the effect of azathioprine is assumed to start 
after 2 to 3 months, it cannot be excluded that azathioprine influenced the 
observed 6-months treatment response. The number of patients treated with 
azathioprine during the follow-up period did not differ between the treatment 
groups (p=0.038). Further studies are needed to study the effect of azathioprine 
on long term outcome.
The results of the present study await confirmation, ideally by controlled 
trials comparing the efficacy and tolerance of low- and high-dose induction 
corticosteroid therapy. However, the relative rarity of the condition makes it 
difficult to perform such studies.
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In conclusion, in this retrospective series response to therapy was comparable 
for AIP patients treated with doses of prednisone in the range of 10 
mg/d - 60 mg/d. These results suggest that low-dose (< 20 mg/d) prednisone 
as initial treatment for AIP is an effective alternative to currently recommended 
higher doses.
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Summary and general discussion 
Samenvatting en conclusies
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SUMMARY AND GENERAL DISCUSSION
Autoimmune pancreatitis is the pancreatic manifestation of a benign 
systemic disease of unknown cause, that shows striking similarity with other 
pancreatobiliary diseases and is highly responsive to steroids. Two types of AIP 
are recognized: type 1 - IgG4 related disease and type 2, which has substantial 
clinical overlap but distinct pathological features. The main clinical challenge 
is its differential diagnosis with malignancy. There is no single diagnostic 
test. Numerous serological tests have been proposed, but most of them lack 
sufficient validation. Diagnosis is made by different sets of diagnostic criteria, 
each with their own focus on particular aspects of the disease, not all equally 
useful or easy to use. We aimed to characterize a group of 114 AIP patients and 
explore the performance of the three major diagnostic criteria systems in this 
group. Second we aimed to establish the extent and cause of misdiagnosis in 
patients that underwent resection for presumed malignancy of the pancreatic 
head. Furthermore we examined the serological profile, including serum total 
IgE and tumor marker Ca 19 - 9 in AIP and other pancreatobiliary disorders with 
a dual purpose: establish their value in differential diagnosis with malignancy 
and gain insight into pathogenesis. Finally we aimed to compare the efficacy of 
low dose versus high dose steroid induction therapy.
The introduction presents AIP in a broader perspective. Chapter 2 describes 
the characteristics and clinical presentation of 114 patients with AIP. 
The performance of the three major diagnostic criteria systems for AIP is 
studied. Recommendations are made which system should preferably be used, 
both generally and in specific diagnostic dilemmas. Chapter 3 is a retrospective 
study on the prevalence of AIP and other benign disorders in patients that 
underwent pancreatoduodenectomy for presumed malignancy of the pancreatic 
head. The preoperative work up is studied and causes of misdiagnosis are 
suggested. Ultimately recommendations are made how to avoid unnecessary 
surgery in AIP patients. In Chapter 4 the tumor marker Ca 19 - 9 is studied in 
AIP and other benign and malignant pancreatobiliary disorders. High levels of 
Ca 19 - 9 are considered distinctive for cancer. Its value in differential diagnosis 
between AIP and pancreatic cancer is examined, both as a single marker and 
in combination with IgG4. Optimal cut-off levels of both markers are assessed. 
In Chapter 5 a pilot study is conducted on possible allergic mechanisms in AIP, 
by studying serum total IgE and its relation to IgG4 in AIP, atopic allergy and 
pancreatic cancer. We also investigate the potential value of IgE in differential 
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diagnosis with pancreatic cancer. In Chapter 6, an extensive immunological 
profile is assessed in AIP and other benign and malignant pancreatobiliary 
disorders. Both general (eg antinuclear antibody, rheumatoid factor) and 
pancreas specific autoantibodies (anti carbonic anhydrase II, anti lactoferrin), 
considered important in pathogenesis and diagnosis, are tested. Ultimately, a 
logistic regression analysis is performed to detect combinations of tests that 
reliably predict a diagnosis of AIP. Finally, in Chapter 7 a retrospective study 
compares the efficacy of high versus low doses of prednisone for induction of 
remission in AIP.
CHARACTERIZATION OF A GROUP OF 114 AIP PATIENTS AND THE 
PERFORMANCE OF THE THREE MAJOR DIAGNOSTIC CRITERIA SYSTEMS IN 
THIS GROUP
Main findings
In general, our series resembles other large cohorts of AIP patients. Only three 
cases of histologically confirmed type 2 AIP were reported. Main differences 
with other cohorts were: a high percentage of elevated Ca 19 - 9 levels (58% 
compared to an average of 25%), 5 cases of AIP associated prostatitis (which 
is not very common) and no case of associated inflammatory bowel disease, 
corresponding with a virtual absence of type 2 AIP. Response (steroid treatment) 
and recurrence rates (98% and 37%) matched those reported in literature. 
At initial presentation, 82% of patients with AIP were correctly identified by any 
of the three major diagnostic criteria systems, without the need for histology. 
The systems proved to be complementary rather than overlapping. In 18% all 
systems failed to confirm the diagnosis. The highest percentage of patients met 
the International Consensus Diagnostic Criteria (ICDC, 68%), followed by HISORt 
criteria (52%) and Asian (33%). The relatively poor performance of the Asian 
criteria in the entire cohort, was mainly due to a low percentage of diagnostic 
pancreatography in this series (51%). If a pancreatogram was available, 
Asian, ICDC and HISORt criteria performed equally well (62% vs 67%, p=0.698 
and 53%, p=0.452, respectively). If abdominal CT showed no pancreatic 
abnormalities (21%), HISORt was the only scoring system that could establish a 
diagnosis of AIP (group C, which requires response to steroid therapy). If IgG4 
levels were normal (18%), AIP was never diagnosed according to the HISORt 
criteria, while the Asian criteria and ICDC established the diagnosis in 42% and 
58% respectively (p=0.517) (Chapter 2)
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Conclusions and further research
The three major diagnostic criteria systems are helpful tools but should not be 
regarded as absolute, gold standard. Based on the results and the usability of 
the systems, we recommend the use of HISORt criteria, except for IgG4 negative 
disease, which is not covered by HISORt. If a pancreatogram is available, the 
relatively straightforward Asian criteria are equally effective (unless CT shows 
normal appearing pancreas, which is not covered by Asian criteria). ICDC can 
be used if diagnosis is still not confirmed, but these criteria are very extensive 
and difficult to use. Noteworthy is the fact that the vast majority (82%) were 
correctly diagnosed without histology, that is before operation (which is 
regarded failure of timely diagnosis) or histological biopsy (which is not widely 
available in the Netherlands).
A large, preferably multicenter, international prospective study is needed to 
validate the diagnostic criteria of AIP, preferably in a diagnostic algorithm. 
Little is known concerning the specificity of the criteria, that is false positivity 
in cancer patients, chronic pancreatitis or sclerosing cholangitis. Furthermore, 
efforts should be made to simplify the International Consensus Diagnostic 
Criteria.
THE EXTENT AND CAUSE OF MISDIAGNOSIS IN PATIENTS THAT 
UNDERWENT PANCREATODUODENECTOMY FOR PRESUMED MALIGNANCY 
OF THE PANCREATIC HEAD
Main findings
In our cohort of 114 AIP patients, one third (32%) had a history of pancreatic 
resection (16%), explorative surgery (14%) or palliative surgery (2%) for 
presumed malignancy, while in retrospect 82% of patients were correctly 
identified preoperatively according to any of the diagnostic criteria systems 
(Chapter 2). The prevalence of benign disease in patients who underwent 
pancreatoduodenectomy in our center was 8.4%. During a 9-year period, seven 
patients were postoperatively diagnosed with AIP, corresponding with a total 
prevalence of 2.6% and accounting for nearly one-third of all benign cases. 
These numbers matched those reported in literature. Based on a preoperative 
index of suspicion of malignancy, surgery could have been avoided in 3 benign 
non-AIP patients. In all AIP patients preoperative findings clearly suggested 
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malignancy. A preoperative diagnosis of AIP was missed for several reasons: 
IgG4 measurements were missing in 6/7 cases, adequate imaging of the 
pancreatic duct was not performed in all and the importance of Ca 19 - 9 
levels was overestimated (2/7 cases). However if diagnostic criteria for AIP 
would have been checked, surgery could have been avoided in one to five 
AIP patients. In two AIP patients, surgery seemed inevitable also in retrospect 
(Chapter 3).
Conclusions and further research
AIP accounts for a significant proportion of incorrect preoperative diagnosis. 
From a quantitative perspective, missing the diagnosis of AIP was a 
problem of limited magnitude. However considering the major therapeutic 
consequences, every effort should be undertaken to establish the correct 
diagnosis. Routine work-up for pancreatic cancer is not enough to detect 
these patients beforehand. IgG4 measurements and systematic use of 
diagnostic criteria systems are recommended for every candidate patient for 
pancreatoduodenectomy when there is no histological proof of malignancy. 
Important clues for diagnosis of AIP are: elevated IgG4, narrowing of the 
pancreatic duct (in contrast with pancreatic carcinoma which usually presents 
dwith double duct dilation) and evidence of extrapancreatic involvement.
To define the clinical usefulness of the preoperative index of suspicion of 
malignancy we used in this study, prospective validation studies are needed. 
In line with this and as already mentioned above, a multicenter, international 
prospective validation study of diagnostic algorithms for AIP is highly desirable.
THE VALUE OF (AUTO)ANTIBODIES AND THE TUMOR MARKER CA 19 - 9 IN 
DIFFERENTIAL DIAGNOSIS BETWEEN AIP AND OTHER PANCREATOBILIARY 
DISEASES
Main findings
First, Ca 19 - 9 and IgG4 levels were studied in several pancreatobiliary diseases, 
ultimately to establish their value in differentiation between AIP and pancreatic 
carcinoma (Chapter 4). Low levels of Ca 19 - 9 were an independent predictor 
of AIP (OR=0.28; 95%CI(0.13 - 0.59), p=0.0001). The optimal cut-off level of Ca 
19 - 9 for detection of AIP was 74 U/ml (upper limit), yielding a sensitivity of 
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73% and specificity of 74%. The optimal cut-off level of IgG4 for differentiation 
with pancreatic cancer was 2.6 g/L (lower limit) yielding a sensitivity of 70% 
and specificity of 100%. Intermediate levels of IgG4 (between 1.4 and 2.6) show 
higher sensitivity (85%), albeit a lower specificity of 81%. If low levels of Ca 
19 - 9 (< 74 U/ml) were combined with IgG4 > 1.0 g/L, specificity rose to 100% 
with a sensitivity of 93%. Thus, low levels of Ca 19 - 9 levels improved both the 
moderate specificity of intermediate IgG4 levels, as the poor sensitivity of high 
IgG4 levels.
Second, the diagnostic value of autoantibodies was studied in groups of 
patients with AIP, various benign and malignant pancreatobiliary diseases 
and Sjögren’s syndrome (Chapter 6). In comparison we also determined the 
diagnostic test characteristics of serum IgG, IgG subclasses, IgE and Ca 19 - 9. 
The seroprevalence of ANA, RF, anticarbonic anhydrase II and anti lactoferrin 
was low and overall comparable for AIP, chronic pancreatitis, pancreatic cancer 
and cholangiocarcinoma. None of the tested autoantibodies was found to be 
discriminative or diagnostically helpful. IgG4 was the best single diagnostic test 
(AUC 0.89). The optimal cut-off level was 2.8 g/L (2x upper limit of normal), 
with a sensitivity of 65% and specificity of 98%. IgG, IgG1, IgG3, IgE and Ca 
19 - 9 levels significantly differed between AIP and malignancy. However, 
their test characteristics are insufficient to be regarded as as useful single 
diagnostics tests. Logistic regression analysis showed that a combination of 
IgG4, IgG3 and Ca 19 - 9 predicted probability of AIP with an AUC of 0.93. 
This combination test awaits confirmation in a validation cohort.
Conclusions and further research
Testing of autoantibodies is not useful in diagnosing AIP. IgG4 is the best single 
test to differentiate between AIP and malignancy, with an optimal cut-off level 
of 2.6 g/L (with respect to pancreatic cancer) or 2.8 g/L (pancreatic carcinoma 
and cholangiocarcinoma combined), that is twice the upper limit of normal. 
This corresponds with high specificity (100 and 98% respectively), but poor 
sensitivity (70 and 65% respectively). The diagnostic performance of Ca 19 - 9 
as a single test to differentiate between AIP and malignancy is poor. However, 
low levels of Ca 19 - 9 (< 74 U/ml) improve both the moderate specificity of 
intermediate IgG4 levels, as the poor sensitivity of high IgG4 levels. Combining 
IgG4, IgG3 and Ca 19 - 9 may be used to reliably predict a diagnosis of AIP, but a 
validation study is needed to determine its use in clinical practice.
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(AUTO)ANTIBODIES AND GAINING INSIGHT IN PATHOGENESIS OF AIP
Autoimmunity is generally considered the major trigger of the inflammatory 
cascade in AIP, but the exact cause remains to be elucidated. Several critical 
comments can be made regarding the presumed predominant autoimmune 
nature of AIP. First, the male predominance and striking steroid responsiveness 
do not match the classical phenotype of autoimmune disease. Second, the 
presence of autoantibodies did not appear to be useful for diagnostic purpose 
(Chapter 6). However, what this means for their putative role in pathogenesis 
remains unclear. In general, studies on autoantibodies in AIP lack validation 
and reproducibility. The latest candidate antigens have been discovered by 
screening AIP sera with a pancreas cDNA library, PCR to produce the peptide 
and subsequent confirmation of the presence of corresponding antibodies with 
ELISA, Western blot or other technique. Most of these highly specific antibodies 
(to pancreatic secretory trypsin inhibitor PTSI, amylase-alpha-2A, heat shock 
protein antibody) show excellent specificity with regard to pancreatic cancer, but 
studies are characterized by very small patient numbers (usally less than 10) and 
await confirmation. For example, to date even the promising a-PBP (Helicobacter 
associated) antibody that was discovered by Frulloni et al in 2009, has not been 
validated. In our opinion it is unlikely that a complex and systemic disease can be 
explained by one autoantigen. The detection of certain antibodies does not prove 
their role in pathogenesis and may reflect a secondary response to inflammation. 
Furthermore, from an etiological point of view it makes no sense that a pancreas 
specific antigen causes a systemic disease. Besides autoimmune (Th1) reactions, 
allergic (Th2) responses are also recognized in the pathogenesis of AIP. IgG4 can 
be induced by prolonged or repeated antigen exposures and is controlled, like 
IgE production, by type T helper (Th2) cells. The presence of allergen-specific 
IgG4 generally means that tolerance inducing mechanisms are activated. IgG4 is 
inefficient in activating complement and forms unstable molecules that are 
unable to cross-link antigens. This may contribute to its anti-inflammatory 
function. In pemphigus, IgG4 antibodies have been shown to be pathogenic in 
mice. The role of IgG4 in AIP, pathogenic or anti-inflammatory, is not known. 
Th2 cytokines interleukin 4 and 13 enhance the production of both IgG4 and IgE 
(both located on the same chromosome). Interleukin 10, produced by regulatory 
T cells shifts the balance between IgG4 and IgE, favoring IgG4 (the so called 
‘modified Th2-response’). Compared to numerous studies on autoimmunity in AIP, 
the role of allergy has been underexposed.
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Main findings
In a pilot study on IgE and IgG4 in 13 patients with AIP (Chapter 5), 12 patients 
with pancreatic carcinoma and 14 patients with atopic allergy, IgG4 and IgE 
levels were studied. Both total IgE and IgG4 levels in patients with AIP were 
significantly higher than those in patients with pancreatic carcinoma (p=0.0004 
and p=0.015 respectively). There was a significant correlation between the 
total IgE and total IgG4 levels in patients with AIP and atopic allergy (rs = 0.82, 
p=0.0006 and rs = 0.88, p< 0.0001, respectively), supporting the view that 
allergic reactions are important in pathogenesis of AIP. The IgE/IgG4 ratio in 
sera from patients with atopic allergy was significantly different (p=0.0012) 
from this ratio in sera from patients with AIP, but this ratio did not differ 
between AIP and pancreatic cancer (p=0.09). We were not able to validate 
the promising results of this pilot study on serum total IgE in the differential 
diagnosis between AIP and pancreatic cancer (AUC of 0.92) in our larger 
prospective study of 33 AIP patients (AUC 0.75) (Chapter 6), most likely due 
to missing values in the AIP group. The optimal cut-off of IgE was 155 kU/L, 
yielding a sensitivity of 67% and a specificity of 81%.
Conclusions and further research
The presence of autoantibodies in AIP is not helpful in diagnosis, but no 
conclusions can be made regarding their role in pathogenesis. Elevated total IgE 
and the correlation between IgE and IgG4 in AIP support the view that allergic 
mechanisms are important in the pathogenesis of AIP. Shifting the focus from 
the initiating auto antibody to the effector IgG4 (and IgE) producing B-cell will 
likely provide more insight in pathogenesis.
THE EFFICACY OF LOW-DOSE VERSUS HIGH-DOSE CORTICOSTEROID 
INDUCTION THERAPY IN AIP
Main findings
A retrospective study compared high-dose (> 20mg/day) versus low-dose 
(≤ 20mg/day) steroid therapy for induction of remission (Chapter 7). A total of 
65 patients were studied (14 on low dose, 51 on high dose). There were no 
significant differences in baseline characteristics between the treatment groups 
including age, presenting symptoms and laboratory results. During a follow-up 
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period of six months all patients responded clinically well. Treatment response 
with respect to symptomatic, radiological and laboratory improvement was 
comparable for the different dosage groups.
Conclusions and further research
In a retrospective unblinded study, no evidence was found for a superior 
treatment effect of high-dose steroid therapy compared to low-dose. 
Based on these data the general recommendation to start with high-dose 
steroid therapy may be reconsidered. These results should be confirmed 
in a prospective randomized controlled trial. Looking beyond the horizon, 
patients included in this trial on steroid induction therapy could be enrolled in 
a prospective study on the maintenance treatment of AIP. Once remission has 
been achieved, patients are randomized to two different treatment arms: low 
dose maintenance steroid therapy and wait-and-see. In case of recurrence off 
steroids, low dose maintenance steroid therapy is compared to wait-and-see 
after remission induction (pulsed steroid therapy). If recurrence occurs on 
steroids, or if a patient is steroid dependent, immunosuppressive therapy is 
started, comparing high dose azathioprine (2.5 mg/kg) with a combination of 
low dose azathioprine (50mg) and low dose prednisone (like in autoimmune 
hepatitis). The relative rarity of the condition makes it difficult to perform such 
studies and once again affirms the importance of international consensus and 
collaboration.
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SAMENVATTING EN CONCLUSIES
Autoimmuun pancreatitis (AIP) is de pancreatische manifestatie van een 
goedaardige systeemaandoening, waarvan de pathogenese niet volledig gekend 
is. Klinisch vertoont AIP sterke gelijkenis met andere benigne en maligne 
aandoeningen van pancreas en galwegen. Veel patiënten ondergaan hierdoor 
onnodige zware chirurgische ingrepen zoals pancreatoduodenectomie of 
partiële hepatectomie, of worden ten onrechte geclassificeerd als irresectabel of 
gemetastaseerd. De ziekte respondeert meestal uitstekend op corticosteroïden. 
Ondanks deze opvallend goede respons worden van oudsher hoge doseringen 
prednison aanbevolen om remissie te induceren. Er bestaan twee types 
AIP, met substantiële klinische overlap maar karakteristieke histologische 
eigenschappen: type 1 (geassocieerd met IgG4 gerelateerde ziekte) en type 2. 
Het stellen van de diagnose AIP is vaak erg lastig. Er bestaat geen enkelvoudige 
diagnostische test. IgG4 is vaak, maar niet altijd verhoogd. Licht verhoogde 
waarden (tussen 1.4 en 2.8 g/l) worden ook aangetroffen bij patiënten 
met chronische pancreatitis of maligniteit. Talloze serologische testen zijn 
onderzocht, met name de aanwezigheid van verschillende autoantilichamen, 
waarbij de daarbij behorende autoantigenen in het algemeen ook worden 
beschouwd als de oorzaak van de inflammatoire cascade in AIP. De meeste van 
deze testen zijn echter onvoldoende gevalideerd. De diagnose wordt gesteld 
door het gebruik van verschillende diagnostische criteria systemen, die niet 
allemaal even bruikbaar of toepasbaar zijn in de dagelijkse praktijk.
Het eerste doel van dit proefschrift was het karakteriseren van een groep van 
114 patiënten met AIP, waarbij de drie belangrijkste diagnostische criteria 
systemen werden getoetst. Ten tweede werd de omvang en de oorzaak van 
misdiagnose onderzocht bij patiënten die een pancreatoduodenectomie 
(Whipple operatie) ondergingen onder verdenking van maligniteit van de 
pancreaskop. Verder werd een uitgebreid serologisch profiel vastgesteld in 
AIP en diverse pancreatobiliaire aandoeningen, (inclusief serum totaal IgE en 
de tumor marker Ca 19.9) met een tweeledig doel: de waarde vaststellen van 
deze markers als diagnostische test en om inzicht te krijgen in de pathogenese 
van AIP. Tot slot werd de effectiviteit onderzocht van lage versus hoge dosis 
prednison remissie inductie therapie.
De introductie (hoofdstuk 1) beschrijft de ziektepresentatie, epidemiologie, 
diagnose, pathogenese en behandeling van AIP. Hoofdstuk 2 beschrijft 
134
de karakteristieken van een cohort van 114 patiënten met AIP. De drie 
belangrijkste diagnostische criteria worden getoetst, waarbij er uiteindelijk 
aanbevelingen worden gedaan welk systeem het beste kan worden gebruikt, 
zowel in het algemeen als in specifieke diagnostische dilemma’s. Hoofdstuk 
3 is een retrospectieve studie naar de prevalentie van AIP en andere benigne 
aandoeningen bij patiënten die een pancreatoduodenectomie (Whipple operatie) 
ondergingen onder verdenking van pancreascarcinoom. De preoperatieve 
work up wordt bestudeerd, waarbij mogelijke oorzaken van foutieve diagnose 
worden onderzocht. Uiteindelijk worden aanbevelingen gedaan om onnodige 
chirurgie te voorkomen bij AIP patiënten. In hoofdstuk 4 wordt de tumor 
marker Ca 19.9 bestudeerd bij AIP en andere benigne en maligne aandoeningen 
van pancreas en galwegen. Hoge waarden van Ca 19.9 worden beschouwd 
als suggestief voor maligniteit. De waarde in de differentiaal diagnose met 
pancreascarcinoom wordt onderzocht, zowel als enkelvoudige test, als in 
combinatie met IgG4, waarbij optimale afkapwaarden worden vastgesteld. 
Hoofdstuk 5 is een pilot studie naar mogelijke allergische mechanismen bij 
AIP. Serum IgE en de relatie tot IgG4 worden onderzocht in AIP, atopische 
allergie en pancreascarcinoom. Ook wordt de potentiële waarde van IgE bij het 
stellen van de diagnose AIP vastgesteld. In hoofdstuk 6 wordt een uitgebreid 
serologisch profiel bepaald bij AIP en andere benigne en maligne aandoeningen 
van pancreas en galwegen. Het doel is om de waarde vast te stellen van het 
testen van autoantistoffen, die belangrijk worden geacht in de diagnose en 
pathogenese van AIP. De diagnostische karakteristieken van multipele testen 
(IgG, IgG subklassen, IgE en Ca 19.9) worden bepaald in het onderscheid tussen 
AIP en maligniteit. Uiteindelijk wordt een logistische regressie analyse verricht 
om combinaties van testen op te sporen die voorspellend zijn voor AIP. Tot slot 
wordt in hoofdstuk 7 een retrospectieve studie beschreven die de effectiviteit 
vergelijkt van lage versus hoge dosis prednison inductie behandeling.
HET KARAKTERISEREN VAN EEN GROEP VAN 114 PATIËNTEN MET AIP 
EN TOETSING VAN DE DRIE BELANGRIJKSTE DIAGNOSTISCHE CRITERIA 
SYSTEMEN
Belangrijkste resultaten
In het algemeen zijn de karakteristieken van onze cohort vergelijkbaar met 
andere beschreven cohorten. Er waren slechts 3 gevallen van type 2 AIP. 
De belangrijkste verschillen met andere cohorten waren een hoog percentage 
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verhoogde Ca 19.9 waarden (58% versus gemiddelde van 25%) en kleine 
verschillen in extrapancreatische manifestaties: 5 gevallen van autoimmuun 
prostatitis (weinig gerapporteerde orgaanmanifestatie) en het ontbreken 
van inflammatoire darmaandoeningen. Op basis van de gegevens bij initiële 
presentatie (dus voordat eventuele operatie plaatsvond) kon 82% van de 
patiënten correct worden geïdentificeerd met behulp van de drie belangrijkste 
diagnostische criteria systemen, zonder histologisch bewijs. In 18% van de 
patiënten kon de diagnose niet worden gesteld. De Internationale Consensus 
Diagnostische Criteria (ICDC) voldeden bij 68%, de HISORt bij 52% en de 
Aziatische criteria bij 33% van de patiënten. De Aziatische criteria deden het 
slechter omdat er slechts in 51% een diagnostisch pancreatogram voorhanden 
was, wat een obligaat criterium is in dit systeem. Indien wel een pancreatogram 
was verricht, bleken de drie systemen gelijkwaardig te zijn. Indien CT een 
ogenschijnlijk normaal pancreas toonde (21%), bleek HISORt het enige systeem 
dat de diagnose kon bevestigen (door middel van prednison proefbehandeling). 
Bij normale IgG4 waarden (18%) kon de diagnose niet worden gesteld met 
HISORt criteria (hoofdstuk 2).
Conclusies en toekomstig onderzoek
De drie belangrijkste diagnostische criteria systemen zijn belangrijke 
hulpmiddelen maar mogen niet als absolute gouden standaard worden 
beschouwd. De HISORt criteria zijn het meest bruikbaar. Als een pancreatogram 
voorhanden is (optioneel), of bij IgG4 negatieve ziekte, worden de relatief 
eenvoudige Aziatische criteria aanbevolen. De zeer uitgebreide ICDC kunnen 
worden gebruikt als de HISORt of Aziatische criteria niet voldoen en de 
verdenking op AIP blijft bestaan.
Een prospectieve studie, bij voorkeur multicentrisch en internationaal, is 
nodig om de diagnostische criteria van AIP te valideren, bij voorkeur in de 
vorm van een diagnostisch algoritme. Er is weinig bekend over de specificiteit 
van de criteria systemen, dat wil zeggen de vals positiviteit met betrekking 
tot maligniteit, chronische pancreatitis of PSC. Daarenboven zouden de 
internationale consensus criteria moeten worden vereenvoudigd, zodat ze ook 
toepasbaar zijn in de dagelijkse praktijk.
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DE OMVANG EN OORZAAK VAN MISDIAGNOSE BIJ PATIËNTEN DIE 
EEN WHIPPLE OPERATIE ONDERGAAN IN VERBAND MET VERDENKING 
MALIGNITEIT
Belangrijkste resultaten
In onze cohort bleek 32% van de patiënten een voorgeschiedenis te hebben van 
Whipple operatie (16%), exploratieve laparotomie (14%) of palliatieve chirurgie 
(2%) wegens vermeende maligniteit, terwijl 82% in retrospectie preoperatief al 
voldeden aan de diagnostische criteria voor AIP (hoofdstuk 2). De prevalentie 
van benigne aandoeningen bij patiënten die een Whipple operatie ondergingen 
onder verdenking van pancreascarcinoom was 8.4%, waarvan 2.6% te wijten 
was aan AIP (hoofdstuk 3). Op basis van een preoperatieve klinische index van 
verdenking op maligniteit, bleken 3 patiënten (niet AIP) ten onrechte geopereerd 
te zijn. Alle patiënten met AIP hadden een hoge verdenking op maligniteit. 
Een preoperatieve diagnose van AIP werd gemist doordat sleutelkenmerken tot 
het stellen van de diagnose AIP ontbraken (IgG4, pancreatogram) of doordat 
het belang van een sterk verhoogd Ca 19.9 werd overschat. In 2 van de 7 AIP 
patiënten was chirurgie onvermijdelijk, ook in retrospectie.
Conclusies en toekomstig onderzoek
Bij 2.6% van de patiënten die worden geopereerd voor pancreaskopcarcinoom 
werd achteraf de diagnose AIP gesteld, dat wil zeggen een derde van alle 
benigne diagnoses (8.4%). Alle patiënten met AIP hadden sterke klinische 
verdenking op maligniteit. Om de diagnose preoperatief te kunnen stellen 
moet actief naar sleutelkenmerken van AIP worden gezocht: verhoogd IgG4, 
pancreatogram, extrapancreatische manifestaties en in geselecteerde gevallen 
een proefbehandeling met prednison. Prospectief onderzoek is nodig om de 
klinische bruikbaarheid van de index van verdenking op maligniteit vast te 
stellen. Zoals eerder genoemd is een multicentrische internationale studie nodig 
naar diagnostische algoritmes voor AIP.
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DE WAARDE VAN (AUTO)ANTILICHAMEN EN DE TUMOR MARKER CA 19.9 
BIJ HET STELLEN VAN DE DIAGNOSE AIP
Belangrijkste resultaten
Ca 19.9 en IgG4 waarden werden bestudeerd in verschillende pancreatobiliaire 
aandoeningen en AIP, met als uiteindelijk doel hun waarde te bepalen in de 
differentiaal diagnose AIP en pancreascarcinoom (hoofdstuk 4). Lage Ca 19 - 9 
waarden bleken een onafhankelijke voorspeller te zijn voor AIP (OR=0.28; 
95%CI(0.13 - 0.59), p=0.0001). De optimale afkapwaarde van Ca 19 - 9 voor de 
detectie van AIP was 74 U/ml, met een sensitiviteit van 73% en specificiteit 
van 74%. De optimale afkapwaarde van IgG4 voor de detectie van AIP bleek 
2.6 g/l (ondergrens), met een sensitiviteit van 70% en specificiteit van 100%. 
Licht verhoogde (intermediaire) waarden van IgG4 (tussen 1.4 en 2.6 g/l) 
zijn sensitiever (85%) maar dit gaat ten koste van een lagere specificiteit van 
81%. Door laag Ca 19.9 (< 74 kU/l) te combineren met een IgG4 van > 1.0, 
stijgt de specificiteit naar 100% en de sensitiviteit naar 94%. In hoofdstuk 6 
werd de diagnostische waarde van autoantilichamen onderzocht bij groepen 
patiënten met AIP, maligne en benigne pancreatobiliaire aandoeningen en 
syndroom van Sjögren. Ook werden de testkarakteristieken vergeleken tussen 
IgG, IgG subklassen, IgE en Ca 19.9, voor het onderscheid tussen AIP en 
maligniteit (pancreas- en cholangiocarcinoom gecombineerd). De prevalentie 
van de autoantistoffen ANA, rheuma factor IgM, anticarboanhydrase II en 
antilactoferrine was laag en vergelijkbaar tussen AIP, chronische pancreatitis, 
pancreas- en cholangiocarcinoom. Geen van deze testen bleek bruikbaar voor 
het stellen van de diagnose AIP. IgG4 werd bevestigd als beste enkelvoudige 
test (oppervlakte onder de receiver operating curve AUC 0.89), met een 
optimale afkapwaarde van > 2.8 g/l, dat wil zeggen twee maal de bovengrens 
van normaal, met een sensitiviteit van 65% en specificiteit van 98%. IgG, IgG1, 
IgG3, IgE en Ca 19.9 waren significant verschillend tussen AIP en maligniteit, 
maar hun testkarakteristieken waren onvoldoende om als betrouwbare 
enkelvoudige test te kunnen worden beschouwd. Logistische regressie analyse 
toonde dat een combinatie van IgG4, IgG3 en Ca 19.9 de meest betrouwbare 
voorspeller voor AIP was, met een AUC van 0.93.
138
Conclusies en toekomstig onderzoek
Het bepalen van autoantistoffen is niet nuttig bij het stellen van de diagnose 
AIP. IgG4 is de beste enkelvoudige test om AIP te onderscheiden van 
maligniteit, met een afkapwaarde van twee maal de bovenlimiet van normaal 
(> 2.6 g/L ten opzichte van pancreascarcinoom en > 2.8 g/l ten opzichte 
van pancreas- en cholangiocarcinoom gecombineerd). Dit correspondeert 
met een hoge specificiteit (respectievelijk 100 en 98%), maar een matige 
sensitiviteit (respectievelijk 70 en 65%). Verhoogde waarden van de tumor 
marker Ca 19.9 zijn niet bruikbaar in de differentiaal diagnose tussen 
AIP en pancreascarcinoom. Echter, lage waarden van Ca 19 - 9 (< 74 kU/l), 
gecombineerd met een IgG4 > 1.0 g/L heeft een sensitiviteit van 94% en 
specificiteit van 100%. Ca 19 - 9 verbetert dus het discriminerend vermogen van 
IgG4. Een combinatie van IgG4, IgG3 en Ca 19.9 bleek de beste serologische 
voorspeller van de diagnose AIP, maar deze combinatie moet nog worden 
gevalideerd alvorens de waarde ervan kan worden bepaald in de dagelijkse 
praktijk.
INZICHT VERKRIJGEN IN DE PATHOGENESE VAN AIP
Autoimmuniteit wordt in het algemeen beschouwd als de belangrijkste 
trigger van de inflammatoire cascade bij AIP, maar de exacte oorzaak is niet 
bekend. Er zijn diverse argumenten aan te voeren die tegen het veronderstelde 
predominant autoimmune karakter van deze ziekte pleiten. De ziekte komt 
vooral voor bij mannen en reageert in het algemeen bijzonder goed en 
snel op prednison. Dit komt niet overeen met het klassieke fenotype van 
autoimmuunziekte. Het bepalen van bepaalde autoantistoffen die als belangrijk 
werden beschouwd voor de pathogenese, bleek geen nut te hebben bij het 
stellen van de diagnose. Dit sluit hun vermeende rol in de pathogenese van 
de ziekte niet uit, maar relativeert op zijn minst het belang ervan. In het 
algemeen worden studies naar autoantistoffen gekenmerkt door het ontbreken 
van goede validatie studies, wat mede samenhangt met hun algemene gebrek 
aan reproduceerbaarheid. De recentste kandidaat autoantigenen werden 
opgespoord door min of meer gelijkaardige en complexe technieken: het 
screenen van patiënt sera met een zogenaamde pancreas-cDNA bibliotheek, 
waarop het peptide geproduceerd wordt door middel van PCR, waarna de 
aanwezigheid van de corresponderende autoantistof wordt bevestigd met 
ELISA, Western blot of andere techniek. In onze opinie is het onwaarschijnlijk 
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dat een complexe systeemaandoening kan worden verklaard door één 
autoantigen, waarbij het niet perse logisch dat dit antigen in het pancreas 
moet worden gezocht. Het is zeer wel mogelijk dat autoantistoffen ontstaan 
als reactie op inflammatie (ten gevolge van het vrijstellen van lichaamseigen 
stoffen) en dus een secundair fenomeen vertegenwoordigen. Behalve 
autoimmuun (Th1 cel) reacties, zijn er ook aanwijzingen dat allergische (Th1) 
reacties een rol spelen in de pathogenese van AIP. De productie van allergeen 
specifiek IgG4 betekent normaal gesproken dat tolerantie inducerende 
mechanismen worden geactiveerd. IgG4 is niet goed in staat om complement 
te activeren en vormt instabiele moleculen die niet goed in staat zijn om 
antigenen te binden. Dit draagt bij aan de anti-inflammatoire eigenschappen 
van IgG4. In muizen studies bij pemphigus bleken IgG4-complexen echter 
wel degelijk pathogeen te kunnen zijn. Het is niet bekend of IgG4 bij AIP een 
anti-inflammatoir karakter heeft, of toch pathogene eigenschappen bezit. 
Th2 cytokines, o.a. interleukine 10, verschuiven de balans van IgE productie 
naar IgG4, dit is de zogenaamde “modified Th2-response”. Dit vindt plaats in 
de uiteindelijke effector cel: de immuunglobuline producerende B lymfocyt 
(plasma cel). Allergische fenomenen bij AIP zijn veel minder goed onderzocht 
dan autoimmuunreacties.
Belangrijkste resultaten
In een pilot studie werden IgE en IgG4 waarden bepaald bij AIP (n=13), 
pancreascarcinoom (n=12) en patiënten met atopische allergie (n=14) 
(hoofdstuk 5). Zowel IgG4 als IgE waarden waren significant hoger bij patiënten 
met AIP dan bij pancreascarcinoom. Er was een significante correlatie tussen IgE 
en IgG4 bij patiënten met AIP en allergie, niet bij pancreascarcinoom. De IgE/
IgG4 ratio van patiënten met allergie was signifcant verschillend van deze ratio 
bij AIP, maar deze ratio was niet verschillend tussen AIP en pancreascarcinoom. 
IgE had in deze pilot studie een uitstekende AUC van 0.92 bij de differentiatie 
tussen AIP en pancreascarcinoom. Dit kon niet worden gevalideerd in onze 
prospectieve studie in een cohort van 33 AIP patiënten, waar de AUC 0.75 bleek 
te zijn, meest waarschijnlijk ten gevolge van ontbrekende waarden in de AIP 
groep. De optimale afkapwaarde van IgE was 155 kU/l, met een sensitiviteit van 
67% en specificiteit van 81% (hoofdstuk 6).
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Conclusies en toekomstig onderzoek
De prevalentie van autoantistoffen in AIP is laag en bleek niet nuttig bij het 
stellen van de diagnose AIP, maar op basis van deze resultaten er kunnen 
geen conclusies worden getrokken ten aanzien van hun rol in de pathogenese. 
Verhoogde IgE waarden en de correlatie tussen IgE en IgG4 in AIP ondersteunen 
de hypothese dat allergische mechanismen een rol spelen in de pathogenese 
van AIP. Het is aannemelijk dat verder inzicht kan worden verkregen in de 
pathogenese van AIP als de huidige focus op de rol van autoantigenen, wat toch 
min of meer als zoeken naar indirecte bewijslast kan worden beschouwd, zal 
verschuiven naar de rol van allergie en de IgG4 producerende B-lymphocyt.
DE EFFECITVITEIT VAN LAGE VERSUS HOGE DOSIS PREDNISON INDUCTIE 
THERAPIE BIJ AIP
Belangrijkste resultaten
In een retrospectieve studie werd de effectiviteit vergeleken van hoge dosis 
(> 20mg/dag) versus lage dosis (≤ 20mg/dag) prednison inductie therapie 
(hoofdstuk 7). In totaal werden 65 patiënten geïncludeerd, waarvan 14 lage 
en 51 hoge dosis hadden gekregen. Er waren geen significante verschillen 
in basis karakteristieken tussen de beide behandelgroepen, inclusief leeftijd, 
symptomen en laboratorium afwijkingen. Tijdens een follow up periode van 
zes maanden respondeerden alle patiënten goed. De respons met betrekking 
tot symptomen, radiologische afwijkingen en laboratoriumafwijkingen was 
vergelijkbaar tussen beide behandelgroepen.
Conclusies en toekomstig onderzoek
In een retrospectieve, niet geblindeerde studie bleek een hoge dosis prednison 
(> 20mg/dag) niet effectiever te zijn dan een lage dosis in het induceren 
van remissie in AIP. Prospectief gerandomiseerd gecontroleerd onderzoek 
is nodig naar de inductie behandeling van AIP (lage versus hoge dosis 
prednison), vooraleer deze resultaten kunnen worden geëxtrapoleerd naar 
de dagelijkse praktijk. Idealiter zou deze studie gekoppeld moeten worden 
aan een prospectieve studie met betrekking tot de onderhoudsbehandeling 
van AIP. Zodra door middel van inductie therapie remissie is bereikt, zouden 
patiënten kunnen worden gerandomiseerd naar twee verschillende behandel 
141
armen: lage dosis prednison (5 - 10mg) onderhoudsbehandeling en wait-and 
see. Bij recidief na staken prednison zou moeten worden vergeleken tussen 
wait-and-see na hernieuwde inductie kuur (prednison puls therapie) en alsnog 
onderhoudsbehandeling met lage dosis prednison. Bij het eerste recidief tijdens 
prednison of bewezen prednison afhankelijkheid zou immuunsuppressieve 
behandeling kunnen worden gestart, waarbij hoge dosis azathioprine kan 
worden vergeleken met combinatie azathioprine 50mg met lage dosis 
prednison (conform autoimmuun hepatitis). De zeldzaamheid van de ziekte 
maakt het moeilijk om zulke studies te verrichten, tenzij dit in internationaal 
verband zou worden verricht. Dit onderstreept nogmaals het belang van 
nationale en internationale consensus en samenwerking.
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Achteraf blijven er bepaalde dingen hangen.
Ritjes tussen Rotterdam en Delft, in een bloedhete auto, met een piepschuimen 
doos gevuld met diepgevroren buisjes. Gescharrel in de talloze diepvriezers 
van het MDL lab, die plots bleken te zijn verhuisd naar niet nader omschreven 
lades van vrij ontoegankelijke diepvriezers in een duistere uithoek van het 
EMC. De blaren die dat opleverde omdat ik het aantrekken van handschoenen 
maar tijdsverlies vond. Dagen lang stickertjes op buizen plakken, buisjes 
tellen en doosjes vullen op het MDL lab. Sessies met Bettina Hansen, die als 
een soort tovenares in hoog tempo onbegrijpelijke formules in SPSS invoerde, 
waar ik zo door werd overdonderd dat ik vreesde het nimmer te kunnen 
vatten. De immense opluchting toen het statistiek lampje ook voor mij bleek 
aan te gaan. Het schrijven van het eerste artikel, hoofdstuk 3, te midden 
van gejuich en getoeter van Nederlands eerste groepswedstrijd in het WK. 
Vakanties doorgebracht bij mijn ouders, zodat Ben en Marie buiten konden 
spelen terwijl ik boven, net als vroeger, mijn ‘huiswerk’ kon maken. De koppen 
koffie en plakken cake die me dan werden toegestopt en de kusjes en knuffels 
die de kinderen tussendoor even kwamen stelen. De weken die ik in aan bed 
gekluisterd lag: in 2007 door dreigende vroeggeboorte van Ben en Marie 
(inclusief door gynaecoloog opgelegd leesverbod op medische literatuur) terwijl 
intussen het huis werd afgebroken, en in het voorjaar van 2012 door een 
hernia, waar mijn enige activiteit erin bestond onder invloed van hoge dosis 
pijnstillers en frustraties in hoog tempo artikelen te produceren, liggend onder 
het meest fantastische gadget wat ik in tijden heb aangeschaft: de ‘Laptop 
Laidback’. Ach, het was een leuke tijd (citeer Herman Finkers).
Natuurlijk wil ik graag een aantal mensen in het bijzonder bedanken.
Allereerst mijn copromotor Henk van Buuren. Dank voor het vertrouwen. 
Jij wist me erbij te houden door me mijn gang te laten gaan. Autoimmuun 
pancreatitis, of liever: pancreatico-cholangitis, was door jou “ontdekt”. 
Je hebt ongetwijfeld met lede ogen moeten toezien hoe de ene na de 
andere onderzoeksgroep ons voor was met het beschrijven van cohorten. 
Jouw nuchtere kijk op dingen is van onschatbare waarde en vormden het 
tegengif voor mijn neurotische neigingen. Veel onderzoeksideeën (niet 
alle even uitvoerbaar) ontstonden onder het genot van een glas wijn op 
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vrijdagmiddag, het hoogtepunt van de besprekingen. Je neus voor bijzondere 
patiëntenverhalen en rare ziektebeelden (o.a. de herkomst van plantenresten 
in ductus choledochus en de ongemeend heftige gevolgen van aambeien) gaan 
ongetwijfeld nog leiden tot een Ziekte van Van Buuren.
Jorie Buijs. Zonder jou was er geen hoofdstuk 2 en 7, en had ik dit werk 
überhaupt niet kunnen afronden. Je werklust en inzet zijn ongekend. Je hebt me 
achter de vodden gezeten, wat me soms slecht uitkwam, maar uiteindelijk heeft 
geleid tot een vlotte eindspurt. Samen werken is zoveel leuker en inspirerender 
dan in je eentje ploeteren. Op mijn beurt hoop ik ook voor jou een motor te zijn 
om je eigen promotie te verwezenlijken. Je bent een kanjer!
Marco Bruno. Dank dat je samen met Henk het AIP project verder wilde zetten. 
Zeer veel dank voor de deadlines die mij indirect werden toegefluisterd. Ik heb 
ze heimelijk vervloekt maar het was de spreekwoordelijke peper. Dank voor je 
begeleiding!
Ernst Kuipers. Onze gemeenschappelijke roots in de polderklei. Dank voor 
de tweede kans die je me gaf om MDL arts te worden. Nooit gedacht dat de 
prehistorische stekel-vis in het biologie lokaal van meester Speerstra van het 
CSG te Emmeloord nog een onderwerp zou worden in een sollicitatiegesprek. 
Ik was beducht voor je donderpreken: altijd kort, zeer effectief, uitgesproken 
met een brede glimlach. En daarna weer positief verder. Juist die combinatie 
maakt je een top-prof en -leraar.
Bettina Hansen. Rots in de branding! Plannen maken en gegevens verzamelen 
is een ding, de brei verwerken tot overzichtelijke tabellen en grafieken een 
vak wat jij als geen ander beheerst. Oneindig veel dank voor je hulp en geduld 
daarin!
Liesbeth Bakker. Wij ontmoetten elkaar toen mijn buik reeds de omvang 
had van een skippy bal. Desalniettemin zag je het zitten. Onze plannen voor 
de serologische studies kregen vorm te midden van je verhuizing van het 
EMC naar het Reinier de Graaf in Delft. Vele obstakels werden stoïcijns en 
systematisch overwonnen. Verhuizen, verbouwen, kleine kinderen opvoeden, 
financieringsproblemen, gebrek aan mankracht, er was altijd wel een oplossing 
voor en tijd was nooit een issue. Jij hebt altijd geloofd in de afronding van dit 
gebeuren, je doorzettingsvermogen was inspirerend. Ik dank je voor de enorme 
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hoeveelheid werk die je hebt verricht. Ook al was het resultaat van de Elisa’s 
voor ACA II, AE en ALF niet wat we hadden gehoopt, zonder dat was de Grote 
Serumstudie niet gelukt.
Het werk in Delft werd mogelijk gemaakt door velen, waarvoor dank. In het 
bijzonder dank aan Kelly van Ettinger, Milton Gilbert en Manou Batstra.
De mensen van het MDL lab: Jan Franken, Angela Heijens en Hanneke 
van Vuuren. Jullie kenden me aanvankelijk niet, desondanks hebben jullie het 
toegelaten dat ik jullie overlaadde met buisjes uit werkelijk alle hoeken van het 
ziekenhuis. Jullie waren verzamel- en distributie punt. Niet het leukste deel van 
de klus. Dank voor de hulp!
Diana Dufour - van den Goorbergh en Herbert Hooijkaas van het 
immunologie lab in het Erasmus MC. Ondanks gebrek aan mankracht en 
financiën hebben jullie je deel kunnen afronden, waarvoor dank.
Albert van Toorenenbergen, voor het trekken van de IgE pilot studie, het 
auteurschap in je artikel en je vasthoudendheid om dit tot nu toe onontgonnen 
terrein gepubliceerd te krijgen. Monique de Waart van klinische chemie, dank 
voor je hulp met de analyses van de monsters.
Katharina Biermann, Joanne Verheij en Pieter Zondervan, dank voor jullie 
herbeoordelingen van de pathologie. Geen gemakkelijke klus!
Mijn collega’s van de afdeling chirurgie: Chulja Pek, Casper van Eijck en 
Geert Kazemier, dank voor het includeren van patiënten, het beschikbaar 
stellen van geheime diepvriesvoorraden en de hulp bij het Whipple artikel.
Mijn collega’s MDL artsen in opleiding, dank voor jaren lief en leed, 
gedeelde kennis en kunde, in het bijzonder de vriendschap van Joyce, Thjon 
en Husseyn. Mijn kamergenoten in het EMC, Leonieke, Lieke, Edith en 
in ’t laatst: Vincent en Leonie. Doordat ik meestal met (zeer gedreven) arts 
onderzoekers een kamer deelde, bleef ik gemotiveerd om door te gaan. 
Dank dat jullie mijn stinkende klompen, eindeloze getelefoneer met patiënten 
en geratel in dicteerapparaat hebben verdragen.
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Alle MDL artsen in het EMC, in het bijzonder Rob de Man. Ik was niet 
makkelijk te sturen en te begeleiden. Dank voor je geduld en je onuitputtelijke 
medische kennis die je zo rijkelijk met ons hebt gedeeld (en nog!).
Alle maten van de Maatschap Interne geneeskunde / MDL van het 
Amphia Ziekenhuis en in het bijzonder mijn collega’s MDL artsen 
Marno, Marc, Ivar, Tom, Alexander en Joris. Lieve collega’s, dank voor het 
creëren van een inspirerende werkomgeving en het bieden van een warm nest. 
Alexander en Rinske: nu jullie nog!
Verpleegkundigen en medewerkers van de afdeling Endoscopie, Unit 
28, assistentes van de polikliniek van het Amphia en verpleegkundig 
specialisten Pamela, Annemarie en Lia voor het gezamenlijk en vaak 
in nacht en ontij helpen van de enorme hoeveelheden MDL patiënten die 
aan ons voorbij stromen. Jullie verdragen al meer dan twee en half jaar mijn 
perfectionisme, hyperactiviteit, ochtendhumeur en overmatige behoefte aan 
cafeïne. Dank!
Alexandra dank voor je liefde en zorg voor ons als gezin, de periode in 
Rotterdam hadden we zonder jou niet overleefd. Marjolein dank voor je 
liefdevolle inzet en zorg in ons Bavelse huishouden.
Mijn ouders en mijn broer Johan, die me hebben geleerd om door te zetten. 
Jullie hebben me de grenzen, maar vooral alle ruimte gegeven om mijn niet 
altijd even realistische dromen na te jagen. Als ik weer eens werd teruggefloten 
door de realiteit stonden jullie daar om mij op te vangen, zonder er veel 
woorden aan vuil te maken. Johan, jij hebt verhuizen tot een kunst verheven. 
Na een keer of negen kon ik eindelijk zelf een verhuizer betalen. Toch vertrouw 
ik de piano bij voorkeur toe aan jou.
Mijn lieve nichtje Leonie. Ik heb de eer gehad je te mogen leren hoe je veters 
strikt en je billen afveegt. Jij hebt me geleerd wat je moet doen als de wereld 
stilstaat.
Ben en Marie, onze lieverdjes die ons zoveel vrolijkheid, liefde en inspiratie 
schenken.
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Tot slot, de belangrijkste persoon in mijn leven, lieve Darek, zonder jou was 
dit boekje er niet gekomen. Jij bent het begin en het eind van de cirkel, in alle 
opzichten. Ik ben je oneindig dankbaar voor je liefde, je steun en geduld. Jij gaf 
me de ruimte om dit af te maken, vaak ten koste van jezelf. Het afronden van 
dit proefschrift is ook voor jou een last van je schouders. Op naar ons volgende 
project: ons huisje in Ulvenhout!
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te Breda (dr B Veldhuijzen) en het Sophia Ziekenhuis te Zwolle (Dr van Marwijk 
Kooy, opleider interne geneeskunde, en dr F. Nelis, D. Westerveld en J. Vecht, 
MDL artsen). Vanaf 1999 werkte ze als arts onderzoeker op de afdeling 
gastroenterologie & hepatologie in het Academisch Ziekenhuis van Utrecht (dr 
J. van Hattum), waar ze participeerde in de opzet van de CIRA trial (Hepatitis 
C). Na een half jaar droeg zij dit over aan Hanneke van Soest (nu MDL arts te 
Den Haag), die in 2011 promoveerde op dit onderwerp. Hierna werkte Marianne 
twee en half jaar als huisarts in opleiding in Berchem (Groepspraktijk Fruithof, 
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de spoedeisende geneeskunde (Henry Serruys, Oostende). Na een drie maanden 
durende reis door Zuid Amerika, kwam ze via het Sophia Ziekenhuis (inmiddels 
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In 2004 startte zij de vooropleiding interne geneeskunde in het IJselland 
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volgde zij in het St Franciscus Gasthuis te Rotterdam (drs A. Rietveld). Hierna 
werkte zij 4 jaar als MDL arts in opleiding in het Erasmus Medisch Centrum te 
Rotterdam (dr R.A. de Man, opleider). Op 6 juni 2010 werd zij geregistreerd 
als MDL arts. Sinds 1 september 2010 werkt zij als MDL arts in het Amphia 
Ziekenhuis te Breda.
Marianne woont sinds 2006 samen met Darek Sikorski. In 2007 kregen zij een 
tweeling: Marie en Ben.
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